5-alpha-Reductase deficiency | 2426 |
5-Fluorouracil/oxaliplatin combined therapy | 2030 |
6-Mercaptopurine sensitivity | 1049 |
11β-Hydroxysteroid dehydrogenase type 2 deficiency | 1124 |
22q13.2 deletion syndrome | 1438 |
46,XX/SRY-negative true hermaphrodite | 1946 |
46,XY Disordered sex development and androgenization at adrenarche | 1947 |
A | |
ABCA1 and ACAT2 mutant phenotypes | 815 |
ABCG2 demethylation | 1000 |
ABCG2 inhibitors | 1000 |
ABCG2-ABCB1 synergism | 1000 |
Abdominal and urinary tract infections | 341 |
Abdominal aortic aneurysm | 1125, 1224, 1947, 2152, 2277, 2297, 2336 |
Abdominal surgery | 263 |
Abetalipoproteinemia | 1119, 2292 |
Abnormal uterine bleeding | 456, 535, 621 |
Abscess | 255 |
Absence (petit mal) seizures | 286 |
Acatalasia | 1213 |
Acceleration of transit of barium through small bowel | 687 |
Acetaldehyde-derived DNA adducts | 1593 |
Acetaminophen toxicity | 9 |
Achlorhydria | 78 |
Acid indigestion | 160, 296 |
Acidosis | 691 |
Acne | 248, 255, 412, 672, 731 |
Acne rosacea | 74 |
Acne vulgaris | 61, 74, 276, 707, 718, 2197 |
Acquired idiopathic sideroblastic anemia (AISA) | 2281 |
Acquired immunodeficiency syndrome | 769, 770, 780, 2212, 2215 |
Acromegaly | 94, 415, 539, 572, 2088, 2428 |
ACTH-dependent Cushing’s syndrome | 185 |
ACTH-independent macronodular adrenal hyperplasia | 2090 |
Actinic keratosis | 31, 223, 379 |
Activated polyamine catabolism | 1913 |
Activating mutations in the GNAS gene | 2090 |
Activating transcription factor-4 | 1594 |
Active benign ulcer | 645 |
Activins and Inhibins | 1947 |
Acute agitation | 805 |
Acute and chronic respiratory tract infections | 700 |
Acute asthma | 673, 804, 1075, 1267 |
Acute bacterial otitis media | 129, 137 |
Acute bacterial sinusitis | 63, 426 |
Acute bronchitis | 745 |
Acute bronchospasm | 673, 745 |
Acute cardiac ischemic events | 3 |
Acute coronary syndrome | 176, 739, 746, 1035, 1268, 1407, 2016, 2206, 2368 |
Acute eosinophilic leukemia (AEL) | 1046 |
Acute exacerbation of chronic bronchitis | 128, 129, 130, 162, 435, 503, 664, 731, 768 |
Acute exacerbation of multiple sclerosis | 186 |
Acute gout | 5, 724 |
Acute gouty arthritis | 291, 617, 709, 764 |
Acute graft vs host disease | 2215, 2444 |
Acute heart failure | 227, 636, 637, 1071 |
Acute hepatic porphyria | 1100 |
Acute herpes zoster | 779, 810 |
Acute hypoxia | 556, 1643 |
Acute intermittent porphyria | 152, 356 |
Acute intestinal amebiasis | 743 |
Acute iritis | 773 |
Acute iron intoxication | 206 |
Acute ischemic events | 87 |
Acute ischemic stroke | 25, 611, 1079 |
Acute leukemia | 373, 836, 1594 |
Acute lymphoblastic leukemia (ALL) | 465, 836, 932, 966, 1025, 1280, 1643, 2063, 2084, 2108, 2137, 2182, 2248, 2255, 2286, 2297, 2316, 2368, 2405, 2477, 2480, 2527 |
Acute lymphocytic (lymphoblastic) leukemia | 190 |
Acute lymphocytic leukemia | 52, 195, 569, 723, 792 |
Acute manic episodes | 49, 635, 805 |
Acute maxillary sinusitis | 129 |
Acute mountain sickness | 8, 2299 |
Acute myeloblastic leukemia | 1439, 2435 |
Acute myelocytic leukemia | 190 |
Acute myelogenous (nonlymphocytic) leukemia | 734 |
Acute myelogenous leukemia | 340, 675, 795, 1046, 2331 |
Acute myeloid leukemia | 195, 305, 373, 836, 966, 1000, 1440, 1643, 1987, 2021, 2063, 2119, 2237, 2279, 2393 |
Acute myocardial failure | 643 |
Acute myocardial infarction | 25, 482, 611, 626, 651, 703, 1072, 1250, 2518 |
Acute organ rejection | 197 |
Acute otitis media | 63, 134, 167, 709, 768, 769 |
Acute pain | 139, 409, 502, 717 |
Acute painful musculoskeletal conditions | 189 |
Acute painful shoulder | 709 |
Acute pancreatitis | 624, 2368 |
Acute promyelocytic leukemia | 50, 763 |
Acute psychotic episodes | 49 |
Acute pulmonary edema | 333 |
Acute pulmonary embolism | 25, 744, 777, 797 |
Acute pyelonephritis | 426 |
Acute rejection of renal transplant | 504 |
Acute renal allograft rejection | 45, 504, 505 |
Acute renal failure | 450 |
Acute respiratory depression | 107 |
Acute respiratory syndrome | 2055 |
Acute rhinitis | 556 |
Acute sinusitis | 162 |
Acute temporomandibular joint pain | 472 |
Acute tenosynovitis | 764 |
Acute upper gastrointestinal bleeding | 1381 |
Acute/subacute bursitis | 764 |
Acute-phase reaction | 812 |
ADA deficiency | 1048 |
Addictive disorders | 1351 |
Addictive behavior | 1989 |
Adenocarcinoma | 308, 1113, 1280, 2027, 2375 |
Adenocarcinoma of breast or ovary | 736 |
Adenocarcinoma of stomach or pancreas | 494 |
Adenoid cystic carcinoma | 2238 |
Adenoma or hyperplastic polyp risk | 2366 |
Adenomatous polyposis coli | 1113 |
Adenosine deaminase deficiency | 569 |
Adenoviral vectors | 1644 |
Adiponectin | 815, 1060 |
Adiposity | 2036, 2206 |
Adjunct anesthetic in ophthalmic surgery | 624 |
Adolescent idiopathic scoliosis | 2206, 2290 |
Adrenal adenomas | 1934 |
Adrenal steroidogenesis | 1934 |
Adrenocortical carcinoma | 495 |
Adrenocortical insufficiency | 186, 187, 312, 363, 764 |
Adrenogenital syndrome | 312 |
Adriamycin-induced glomerulosclerosis | 1125 |
Adult-onset hypogonadotropic hypogonadism | 1947 |
Advanced macular degeneration | 2250 |
Adverse drug effects | 2491 |
AEBP1 (Adipocyte enhancer-binding protein 1) | 1125 |
Aerodigestive tract cancer | 1594 |
Aflatoxin-related hepatocarcinogenesis | 2108 |
African trypanosomiasis | 712 |
Age- and sex-related effects | 1481 |
AGER/NOTCH4 | 1126 |
Age-related changes | 836, 988, 1001, 1359, 1440, 1594, 1645, 1913, 1947 |
Age-related differences | 1381 |
Age-related eye disorders | 2102 |
Age-related hearing impairment | 2119 |
Age-related macular degeneration | 1125, 1245, 2133, 2136, 2143, 2452 |
Age-related macular degeneration type 5 | 2033 |
Age-related macular dystrophy | 2450 |
Aggression-related traits | 988 |
Aggressive behavior | 1947, 2160 |
Aggressive fibromatosis | 2238 |
Aging | 932, 1126, 1487, 1489 |
Agitated states | 810 |
Agitation | 37 |
Agranulocytosis | 1457 |
AICA-ribosiduria | 1191 |
AIDS | 967, 2126, 2130, 2133, 2136, 2206, 2182 |
AIDS-related Kaposi’s sarcoma | 387, 559, 791 |
Airway diseases | 673 |
Airway obstruction | 381, 726, 732 |
Albright hereditary osteodystrophy | 2090 |
Alcohol (Ethyl) biodisposition | 1056 |
Alcohol abstinence | 4 |
Alcohol abuse | 1054, 2079 |
Alcohol consumption | 2305 |
Alcohol dependence | 1052, 1054, 1055, 1104, 1250, 1255, 1266, 1997, 2160, 2419 |
Alcohol dependence, susceptibility to | 1250, 1255, 1997, 2079 |
Alcohol metabolism and alcoholism | 1055, 1101, 1467 |
Alcohol use disorders | 147, 1595 |
Alcohol-associated cancer | 1055 |
Alcoholic cardiomyopathy | 1595 |
Alcoholic fatty liver | 2343 |
Alcoholic liver cirrhosis | 1595 |
Alcoholic liver disease | 1054, 1105, 1467, 2215 |
Alcoholic steatohepatitis | 1595 |
Alcohol-induced liver injury | 1595 |
Alcoholism | 166, 733, 1054, 1055, 1065, 1101, 1105, 1647, 1999, 2322, 2394, 2398 |
Alcoholism, susceptibility to | 1065, 1999 |
Alcohol-related breast cancer | 1056 |
Alcohol-related cancer | 1054 |
Alcohol-related colorectal cancer | 1056 |
Alcohol-related pathology | 1105 |
Aldosterone synthase (CYP11B2) | 1935 |
Aldosterone synthase (CYP11B2) inhibitors | 1935 |
Aldosterone synthase deficiency type I | 1935 |
Aldosterone-producing adenomas | 1934 |
Alert classifications in product labeling | 1647 |
Allergic asthma | 544, 673, 804 |
Allergic conditions | 622 |
Allergic conjunctivitis | 62, 75, 266, 771 |
Allergic dermatosis | 232, 610, 613 |
Allergic disorders | 187, 613 |
Allergic rhinitis | 54, 62, 95, 211, 232, 254, 322, 425, 499, 551, 764, 771, 1648, 2438 |
Allergic skin manifestations | 771 |
Allergic states | 613, 764 |
Allergy | 214, 232, 613 |
Allogenic bone marrow transplantation | 675 |
Alloimmune thrombocytopenia | 2226 |
Alloimmunity | 837 |
Alopecia areata | 764 |
Alpers’ syndrome | 2334 |
Alpers-Huttenlocher syndrome |
2334 |
alpha-1-Antitrypsin deficiency | 23 |
Altitude illness | 1935 |
Alveolar echinococcosis | 1650 |
Alzheimer’s disease 1, APP-related | 1165 |
Alzheimer’s disease, susceptibility to | 812, 1195, 1220, 1249, 1263, 2071 |
Alzheimer’s disease | 166, 240, 272, 335, 360, 460, 713, 750, 805, 812, 816, 837, 988, 991, 1001, 1029, 1094, 1109, 1115, 1126, 1165, 1195, 1202, 1211, 1213, 1220, 1224, 1230, 1249, 1258, 1263, 1441, 1948, 1980, 2036, 2071, 2100, 2112, 2113, 2127, 2130, 2146, 2158, 2169, 2192, 2206, 2211, 2215, 2242, 2258, 2263, 2281, 2299, 2303, 2307, 2319, 2332, 2336, 2349, 2358, 2369, 2419, 2422, 2444, 2455, 2470, 2518 |
Ambient particulate matter | 1280 |
Amblyopia | 166 |
Amebiasis | 229 |
Amebic liver abscess | 743 |
Amebic meningoencephalitis | 39 |
Amenorrhea | 535, 2036 |
Aminoglycoside-induced and nonsyndromic hearing loss | 2281, 2282 |
Aminoglycoside-induced deafness | 2284 |
AMME complex | 1044 |
Amnestic dementia | 1128 |
Amyloid A3 | 1948 |
Amyloid polyneuropathy-nephropathy Iowa type | 1116 |
Amyotrophic lateral sclerosis | 656, 839, 1111, 1129, 2360 |
Anaerobic bacterial and protozoal infections | 483 |
Anaerobic infections | 377 |
Analgesic response | 2267 |
Anaphylactic reactions | 266, 622 |
Androgen deficiency | 728 |
Androgen insensitivity syndrome | 1184 |
Androgenetic alopecia | 492 |
Anemia | 202, 268, 269, 366, 511, 556, 2227 |
Aneurysm | 1129 |
Angina | 355, 399, 525, 742, 2060 |
Angina pectoris | 41, 56, 227, 399, 403, 482, 507, 533, 626, 742, 788, 2060 |
Angioedema | 121, 184, 771 |
Angiofibroma | 2268 |
Angiogenesis | 1129, 1615 |
Angiotensin-converting enzyme inhibitor (ACEi)-induced cough | 2361 |
Angle-closure glaucoma | 222, 256, 590 |
Anhaptoglobinemia | 2152 |
Ankylosing spondylitis | 5, 11, 139, 223, 284, 291, 348, 383, 384, 512, 709, 724, 1273, 1444, 2133, 2136, 2192, 2429, 2465 |
Anogenital pruritus | 78, 212, 226, 253, 610 |
Anorectal surgical wounds | 798 |
Anorexia | 249, 458, 2036, 2161, 2398, 2476 |
Antagonistic pleiotropy | 1129 |
Anterior cruciate ligament (ACL) ruptures | 1261 |
Anterior uveitis | 657 |
Anthropometric parameters | 1949 |
Antibiotic-associated pseudomembranous colitis produced by Clostridiuim difficile | 783 |
Antibody-induced pure red cell aplasia | 190 |
Anticholinesterase inhibitor poisoning | 59 |
Anticonvulsant hypersensitivity syndrome | 2021 |
Antidepressant exposure in breastfed infants | 1557 |
Antidepressants in late pregnancy | 1555 |
Antihypertensive therapy | 2023, 2304 |
Anti-inflammatory phenotype | 1130 |
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) | 1273 |
Antiphospholipid syndrome | 1381, 2056 |
Antipsychotic-induced extrapyramidal side-effects | 1523 |
Antipsychotic-induced obesity | 2005, 2165 |
Antipsychotic-induced parkisonism | 2380 |
Antipsychotic-induced side-effects | 1063 |
Antipsychotic-induced tardive dyskinesia | 2002, 2004, 2289 |
Antiretroviral therapy | 1224 |
Antiretroviral therapy-associated lipid disorders | 1130 |
Antisocial behavior | 2259 |
Antithrombotic therapy | 1407 |
Anti-tuberculosis drug-induced hepatic injury | 2496 |
Anti-tuberculosis drug-induced hepatitis | 1407 |
Anti-tuberculosis drug-induced maculopapular eruption | 1381 |
Antitumor prodrug development | 1658 |
Anti-VEGF therapy | 1130 |
Antley-Bixler craniosynostosis syndrome (cytochrome P450 oxidoreductase deficiency) | 1949, 1957 |
Anthracycline-induced extravasation | 217 |
Anuria | 450 |
Anxiety disorder | 23, 35, 37, 93, 102, 103, 144, 147, 177, 220, 245, 251, 368, 439, 450, 464, 552, 620, 702, 1061, 2079, 2476 |
Anxious depression | 450, 2305 |
Aortic aneurysm | 2290 |
Aortic coarctation | 1935 |
Aphthous ulcers | 119, 449 |
Aplastic anemia | 45, 1659, 2182, 2441, 2444 |
Apnea | 244, 1130, 1195 |
Apnea of prematurity | 107, 732 |
ApoA-I mimetic peptide 4F | 1130 |
ApoB-100 | 1130 |
APOE and lipid metabolism | 1128 |
APOE haplotype | 1131 |
APOE in Alzheimer’s disease | 1126, 1128 |
ApoE receptor 2 | 1131 |
ApoE-/- PGC-1α-/- mice | 1131 |
ApoE-1 mimetic peptide D4-F | 816 |
APOE-related phenotypic profiles in Alzheimer’s disease | 1128 |
Apolipoprotein B peptide vaccine | 1131 |
Apolipoprotein E 72-166 peptides | 1131 |
Apoptosis | 989 |
Apoptosis signal-regulating kinase 1 | 1131 |
APP and presenilins in Alzheimer’s disease | 1166 |
APP-related cerebral amyloid angiopathy | 1169 |
Argininemia | 1189 |
Ariboflavinosis | 653 |
Aromatase (CYP19A1) | 1949 |
Aromatase and dual aromatase-steroid sulfatase inhibitors | 1950 |
Aromatase deficiency | 1949 |
Aromatase excess syndrome | 1949 |
Aromatase inhibitor-induced arthralgia in breast cancer | 1950 |
Aromatase inhibitors vs Tamoxifen in advanced breast cancer | 1951 |
Aromatic L-amino acid decarboxylase deficiency (AADC) | 1448, 1989 |
Arrhythmia | 565, 2389 |
Arsenic metabolism | 1190 |
Arsenic poisoning | 2112, 2113 |
Arsenic toxicity | 2119 |
Arsenic-induced disease | 1190, 1220 |
Arterial hypertension | 612, 626, 636, 643, 650, 701, 720, 725, 742, 757, 758, 765, 782, 788, 1063, 1068, 1071, 1077, 1081, 1197, 1202, 2014 |
Arterial properties | 1051 |
Arteriosclerosis | 182, 1914, 2521 |
Arteriosclerosis obliterans | 401 |
Arteriovenous fistula stenosis | 2277 |
Arthralgia | 234 |
Arthritis | 144, 155, 284, 455, 673, 772 |
Arthrosis | 724 |
Aryl hydrocarbon receptor | 841, 1002, 1132, 1280, 1337 |
Aryl hydrocarbon receptor-interacting protein (AIP) | 1306 |
ASA-intolerant myocardial infarct | 2439 |
Asbestosis | 2114 |
Ascites | 15, 285 |
Aseptic prophylaxis of burns | 685 |
Aspergillosis | 402 |
Aspergillus infection | 39, 126, 2452 |
Aspirin hypersensitivity | 2202 |
Aspirin intolerance | 1382 |
Aspirin-induced asthma | 2311, 2439 |
Aspirin-induced peptic ulcer | 1381, 2439 |
Aspirin-intolerant asthma (AIA) | 2360, 2361, 2362, 2363, 2366 |
Assisted Reproductive Technology | 621, 777 |
Association of APOE with beta-amyloid and tau proteins in AD pathology | 1127 |
Association of APOE-4 with an anticipation of the age-at-onset and fast cognitive decline | 1127 |
Association of CYP2D6 variants with Alzheimer’s disease-related genes | 1442 |
Asthma | 69, 97, 187, 211, 253, 322, 328, 467, 499, 500, 673, 801, 804, 933, 1044, 1048, 1050, 1075, 1109, 1116, 1214, 1225, 1267, 1271, 1273, 1337, 1408, 1615, 1980, 2055, 2105, 2112, 2115, 2182, 2202, 2219, 2224, 2256, 2349, 2361, 2369, 2417, 2437, 2439, 2444, 2452, 2514 |
Asthma, susceptibility to | 1075 |
Astrocyte elevated gene-1 (AEG1) | 841 |
Astrocytes | 1132 |
Astrocytic and oligodendroglial brain tumors | 1002 |
Astrocytoma | 124, 721, 1002, 2115 |
Asystole | 59, 266, 785 |
Ath29 | 1132 |
Atherosclerosis | 57, 323, 611, 667, 816, 989, 1089, 1109, 1116, 1132, 1225, 1244, 1269, 1663, 1935, 1980, 2056, 2060, 2092, 2222, 2248, 2325, 2327, 2339, 2341, 2343, 2362, 2384, 2444, 2465 |
Atherosclerosis, susceptibility to | 1269, 2092 |
Athlete’s foot | 681, 692, 707, 725, 753, 763, 776 |
Atopic dermatitis | 42, 78, 314, 322, 590, 714, 2202, 2219 |
ATP-binding cassette transporter G1 deficiency | 989 |
Atrial fibrillation | 6, 238, 250, 279, 372, 618, 623, 626, 637, 699, 788, 789, 797, 1030, 1085, 1935, 2304 |
Atrial flutter | 250, 279, 372, 618, 626, 699, 788 |
Atrioventricular nodal block | 265 |
Attention-deficit hyperactivity disorder (ADHD) | 38, 56, 216, 218, 255, 432, 470, 478, 787, 1063, 1065, 1068, 1351, 1997, 2005, 2007, 2090, 2160, 2161, 2162, 2259, 2260, 2394, 2396, 2398, 2418, 2476 |
Attention-deficit hyperactivity disorder, susceptibility to | 1063, 1065, 1068, 1997, 2005, 2007, 2090 |
Atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung | 1951 |
Atypical depression | 2259 |
Autism | 1048, 1061, 1951, 2095, 2108, 2162, 2166, 2226, 2258, 2270, 2289, 2318 |
Autism spectrum disorder | 658, 1061, 2095, 2289, 2318 |
Autistic disorder | 658, 2318 |
Autoimmune Addison’s disease | 1273 |
Autoimmune disorders | 1273, 2401 |
Autoimmune hemolytic anemia | 190 |
Autoimmune hepatitis | 1449, 1540, 2143 |
Autoimmune hypothyroidism | 2203 |
Autologous hCD40L/IL-2 tumor vaccine | 1002 |
Autonomic nervous system dysfunction | 2005 |
Autosomal dominant dopa-responsive dystonia | 2081 |
Autosomal dominant periodic fever syndrome | 2465 |
Autosomal dominant retinitis pigmentosa | 2223 |
Autosomal dominant thrombophilia | 2353 |
Autosomal dominant type III hyperlipoproteinemia | 1132 |
Autosomal recessive dopa-responsive dystonia with or without hyperphenylalaninemia | 2081 |
Autosomal recessive juvenile Parkinson’s disease 2 | 2326 |
Autosomal recessive mental retardation 6 | 2095 |
Autosomal recessive spastic paraplegia 7 | 2425 |
Autosomal recessive thrombophilia | 2353 |
AV nodal block | 59, 398 |
AV nodal re-entrant tachycardias | 626 |
AWP1 Protein characterization | 2529 |
Axenfeld-Rieger syndrome | 1337 |
Axillary node tumor | 267 |
Azoospermia, oligospermia | 1233, 1665, 2119 |
B | |
B-cell chronic lymphocytic leukemia | 18, 380 |
Babesia microti infection | 638 |
Bacillus Calmette-Guérin and Salmonella infection | 2219 |
Bacillus Calmette-Guérin-refractory carcinoma in situ of the urinary bladder | 781 |
Bacterial conjunctivitis | 63, 426, 503, 613, 707 |
Bacterial Eikenella corrodens infections | 133 |
Bacterial infections | 39, 137, 178, 208, 255, 276, 341, 380, 430, 483, 492, 558, 575, 576, 594, 598, 769 |
Bacterial infections of the eye | 316 |
Bacterial meningitis | 465 |
Bacterial sepsis | 2466 |
Bacterial septicemia | 137, 377 |
Bacterial sinusitis | 503 |
Bacterial vaginosis | 169, 412, 483, 743 |
Baldness | 1185 |
Balkan endemic nephropathy | 1666 |
Bariatric surgery | 990 |
Bariatric surgery-induced weight loss | 1596 |
Barrett’s metaplasia | 1666 |
Bartter- and Gitelman-like syndromes | 1936 |
Basal cell carcinoma | 316, 379 |
Basal cell nevus syndrome | 1281, 1450, 2109 |
B-cell lymphoma | 843 |
Beckwith-Wiedemann syndrome | 2190 |
Bee stings | 73, 255 |
Behavioral symptoms | 1133 |
Behcet’s disease | 732, 1274, 2176, 2206, 2212, 2224, 2401, 2455 |
Beneficial body composition | 2316 |
Benign essential blepharospasm |
2007 |
Benign facial lentigines | 718 |
Benign familial tremor | 617 |
Benign gastric ulcer | 296, 415, 534, 545, 645 |
Benign metastasizing leiomyoma | 1951 |
Benign prostate hyperplasia | 19, 252, 612, 685, 716, 725, 1063, 1098, 1666, 1951 |
Benzene toxicity | 1596, 2021, 2109, 2307 |
Benzodiazepine intoxication | 312 |
Benzodiazepine-induced sedation | 312 |
Berardinelli-Seip congenital generalized lipodystrophy (type 1) | 1083 |
Beryllium disease | 2138 |
beta-Amyloid | 817 |
beta-Hemolytic streptococci | 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 140, 178, 540, 549 |
beta-Thalassemia | 977, 2125 |
Bilateral adrenal incidentalomas | 2316 |
Bilateral striatal necrosis | 2280, 2283 |
Bile acid homeostasis | 1914 |
Bile acid metabolism | 1668 |
Bile acid-activated vitamin D receptor signaling | 1914 |
Bile salt deficiency | 456 |
Biliary and renal colic | 368 |
Biliary atresia | 2518 |
Biliary cholesterol excretion | 844 |
Biliary epithelium | 1669 |
Biliary tract cancer | 1408 |
Biliary tract infections | 129 |
BIN1 | 1133 |
Bioartificial liver systems | 1669 |
Biotin deficiency | 84 |
Biotransformation of antidepressants | 1444 |
Bipolar I disorder | 52, 118, 414, 541, 635, 658 |
Bipolar affective disorder | 658, 2396, 2428 |
Bipolar depression | 658 |
Bipolar disorder | 49, 434, 635, 658, 781, 805, 808, 810, 1210, 1258, 1991, 1997, 2003, 2009, 2062, 2096, 2100, 2158, 2162, 2167, 2188, 2398, 2476 |
Bipolar mania | 635, 658, 781 |
Birdshot chorioretinopathy | 2130 |
Birth weight | 2306 |
Birth weight and metal toxicity | 2128 |
Bisallylic hydroxylation | 1669 |
Bisphosphonate-related osteonecrosis in multiple myeloma | 1371 |
Bladder cancer | 68, 164, 247, 494, 791, 844, 1094, 1235, 1240, 1282, 1307, 1338, 1450, 1670, 1903, 2027, 2109, 2203, 2239, 2251, 2294, 2297, 2470, 2498, 2507, 2518, 2527 |
Bladder outlet obstruction | 1952 |
Bladder overactivity | 202 |
Bladder tumors | 791, 1240, 1903, 2251, 2290 |
Blastocystis hominis infections | 391 |
Blastomyces dermatitidis | 39, 514 |
Blastomycosis | 310, 402, 407 |
Bleeding disorder | 2325, 2439 |
Blepharitis | 514 |
Blepharospasm | 90 |
Blood | 1670 |
Blood lead levels | 1100 |
Blood lipids | 1915, 2226 |
Blood pressure | 1670, 1936, 2395 |
Blood pressure regulation | 1225 |
Blood-brain barrier | 844, 934, 1003, 1133, 1282, 1338, 1670 |
Blood-testis barrier | 845 |
Body bone mineral density | 2343 |
Body mass index | 1080, 2154 |
Body weight loss | 1082, 1468 |
Bone and joint infections | 128, 129, 132, 133, 137, 138, 140, 162, 377, 740 |
Bone development | 2071 |
Bone fracture risk | 1261 |
Bone infections | 140, 341, 377, 740 |
Bone loss | 1952 |
Bone marrow transplantation | 305, 845 |
Bone metabolism | 1671 |
Bone metastases of malignancy |
171 |
Bone metastases of solid tumors |
806 |
Bone mineral density | 18, 1044, 2036, 2043, 2206 |
Bone morphogenetic protein-2 (BMP-2) | 1952 |
Bone structural traits | 1133 |
Bowel disease | 224, 592 |
Brachytic2/ZmABCB1 | 846 |
Bradyarrhythmias | 398 |
Bradycardia | 265, 1450 |
Bradycardia-induced long QT syndrome | 2231 |
Brain | 846, 934, 1003, 1468, 1615, 1936, 1980 |
Brain apolipoproteins | 1133 |
Brain aromatase | 1952 |
Brain arteriovenous malformations | 1047 |
Brain cancer | 2294 |
Brain CYP2B | 1359 |
Brain CYP2D6 | 1451 |
Brain CYP2E1 | 1597 |
Brain CYP3A4 | 1672 |
Brain injury | 1953 |
Brain metabolism | 1496 |
Brain microvessels | 1338 |
Brain penetration | 846 |
Brain serotonin receptor binding | 1447 |
Brain steroidogenesis | 1953 |
Brain tumors | 124, 436, 619, 845, 1672, 2527 |
Brain white matter lesions | 1134 |
Brain-derived neurotrophic factor | 1134 |
Brainstem glioma | 124 |
BRCA1/BARD1 complex | 1954 |
Breast and endometrial carcinoma | 458 |
Breast and other epithelial carcinomas | 1271 |
Breast cancer | 42, 81, 146, 190, 237, 247, 267, 274, 281, 293, 316, 318, 349, 373, 404, 421, 473, 494, 511, 559, 562, 641, 715, 728, 756, 791, 792, 793, 846, 934, 981, 1003, 1027, 1054, 1089, 1094, 1107, 1113, 1194, 1206, 1208, 1214, 1221, 1230, 1233, 1235, 1237, 1249, 1261, 1263, 1282, 1307, 1338, 1371, 1382, 1402, 1408, 1452, 1597, 1672, 1954, 1999, 2016, 2024, 2027, 2036, 2043, 2105, 2109, 2115, 2119, 2151, 2156, 2188, 2213, 2222, 2239, 2247, 2261, 2271, 2286, 2294, 2299, 2307, 2333, 2336, 2411, 2416, 2432, 2436, 2441, 2444, 2448, 2470, 2480, 2487, 2496, 2504, 2507, 2510, 2526, 2527 |
Breast cancer chemoprevention | 1955, 1954 |
Breast cancer, invasive | 641, 715 |
Breast cancer, susceptibility to | 1249, 1261, 1263, 1999, 2336 |
Breast, head and neck, and lung carcinomas | 473, 792 |
Breast-ovarian cancer | 1053 |
Bronchial airway hyperactivity | 469 |
Bronchial asthma | 157, 265, 266, 516, 726, 764 |
Bronchial epithelial and alveolar macrophage cells | 1673 |
Bronchial hyperresponsiveness | 2037 |
Bronchitis | 136, 393, 745 |
Bronchoconstriction | 328 |
Bronchodilator | 664, 726, 750 |
Bronchopulmonary dysplasia | 652, 750 |
Bronchospasm | 265, 266, 313, 328, 393, 673, 745 |
Brucellosis | 704 |
Brugada syndrome | 2386, 2389 |
Brunner syndrome | 2259 |
Buccal mucosa carcinogenesis | 1903 |
Budd-Chiari syndrome | 2049 |
Bulimia nervosa | 317, 2475 |
Burkitt’s lymphoma variant/acute lymphoblastic leukemia with translocations t(2;8)(p12;q24);t(8;22)(q24;q11) | 1025 |
Burkitt’s lymphoma | 190, 967 |
Burns | 15, 255, 287, 608, 610, 685, 699, 724 |
Bursitis | 383, 764, 709, 724 |
Buruli ulcer | 2401 |
C | |
Cachexia | 458, 699 |
CADASIL | 2302 |
Caffey disease | 1261 |
CAG repeat polymorphisms | 1185 |
Calcineurin inhibitor-induced chronic kidney disease | 1615 |
Calcium deficiency | 110, 111, 113 |
Calcium depletion | 110, 112 |
Calcium oxalate calculi | 21 |
Calcium supplementation | 112 |
Camurati-Engelmann disease | 2444 |
Cancer | 848, 1105, 1110, 1134, 1193, 1214, 1453, 1597, 1678, 1992, 2027, 2101, 2102, 2112, 2113, 2286, 2290, 2491, 2526 |
Cancer chemotherapy | 977 |
Cancer chemotherapy-induced nausea and vomiting | 506, 561, 620, 773 |
Cancer metastasis | 1615 |
Cancer pain | 301, 848, 2081 |
Cancer risk | 2510 |
Cancer susceptibility | 2369 |
Candida infection | 39, 310, 725, 795 |
Candidal cystitis | 39 |
Candidemia | 43, 126, 310, 795 |
Candidiasis | 407, 538, 603, 725, 726 |
Candiduria | 407 |
Cannabinoid receptor GPR55 | 934 |
Capillary infantile hemangioma | 2236 |
Carbamazepine hypersensitivity | 2157 |
Carbonic anhydrase II | 1956 |
Carbuncles | 287, 309 |
Carcinogenesis | 1468 |
Carcinoid syndrome | 703, 2268 |
Carcinoid tumor | 703 |
Carcinoid tumors, intestinal | 539 |
Carcinoma | 849, 1615, 2090 |
Carcinoma cells | 2328 |
Carcinoma of the colon or rectum | 395 |
Cardiac arrest | 266, 772, 1597 |
Cardiac arrest and therapeutic hypothermia | 1597 |
Cardiac arrhythmias | 449, 2229, 2386 |
Cardiac bypass surgery | 772 |
Cardiac CYP450s | 1283, 1615 |
Cardiac decompensation | 206, 236 |
Cardiac ischemic complications | 271 |
Cardiac potassium channel KCNA5 | 849 |
Cardiac resuscitation | 112 |
Cardiac valve disease | 1134 |
Cardiac valve replacement | 797 |
Cardiofaciocutaneous syndrome | 1204, 2239 |
Cardiomyopathy | 217, 2284, 2395, 2482 |
Cardiomyopathy and deafness | 2284 |
Cardiomyopathy with or without skeletal myopathy | 2285 |
Cardiopulmonary bypass | 15, 218 |
Cardiopulmonary bypass and coronary artery bypass grafting | 1134 |
Cardiotoxicity | 1549, 1568 |
Cardiovascular adverse events | 1454 |
Cardiovascular disease | 57, 78, 1051, 1057, 1070, 1076, 1080, 1085, 1089, 1095, 1105, 1117, 1120, 1197, 1269, 1371, 1597, 1615, 1936, 1956, 2044, 2051, 2128, 2146, 2152, 2211, 2286, 2299, 2366, 2422, 2452 |
Cardiovascular function | 1067, 1076, 2081 |
Cardiovascular risk | 1447, 2053, 2366 |
Cardiovascular status | 2316 |
Carminative | 780 |
Carotid atherosclerosis | 611, 2306 |
Carotid endarterectomy | 1245 |
Castration | 1683 |
Cataplexy | 693 |
Cataract surgery | 9, 409, 520, 624, 774 |
Cauterization of wounds and sluggish ulcers | 684 |
Caveolin-1-deficiency | 1936 |
CCR5-tropic HIV-1 infection | 451 |
CD34/M-cadherin bone marrow progenitor cells | 1134 |
CD36 | 1134 |
CD44 | 849 |
CD147/basigin | 849 |
CD 437 | 1235, 2062, 2137, 2238, 2347, 2472 |
CD 4528 | 2516 |
CDX2 (caudal-related homeobox transcription factor) | 849 |
Celiac disease | 1274, 1684, 1907, 2139, 2199 |
Cellulites | 309 |
Central core disease | 2383 |
Central hypoventilation syndrome | 2379 |
Central nervous system infections | 39 |
Central nervous system injury | 1257 |
Central nervous system lymphoma | 1004 |
Central obesity | 2316 |
Centronuclear myopathy | 2383 |
Cerebellar ataxia | 2334 |
Cerebral amyloid angiopathy | 1134, 1169, 1936 |
Cerebral contusion | 141 |
Cerebral edema | 214, 450 |
Cerebral infarction | 1907, 2060, 2365 |
Cerebral malaria | 2455 |
Cerebral microhemorrhage and vascular amyloid deposition | 1135 |
Cerebral palsy | 65, 85, 90, 123, 200 |
Cerebral vascular disease | 166, 342, 794 |
Cerebral venous thrombosis | 797, 2048 |
Cerebrooculofacioskeletal syndrome | 2031 |
Cerebrooculofacioskeletal syndrome (type 1) | 2033 |
Cerebrooculofacioskeletal syndrome 4 | 2029 |
Cerebrotendinous xanthomatosis | 1684, 1915, 1981 |
Cerebrovascular accident | 2513 |
Cerebrovascular atherosclerosis | 611, 1135 |
Cerebrovascular disorders | 523, 611, 1135, 1160, 1408 |
Cerebrovascular insufficiency | 272 |
Cervical cancer | 359, 755, 793, 1225, 2025, 2057, 2192, 2307, 2444, 2471 |
Cervical dystonia | 91, 2007 |
Cervical neoplasia | 755, 793, 2438 |
Cervical/urethral gonorrhea | 131, 162, 540, 700, 731 |
Cervicitis | 63, 540 |
Cervicocerebral artery atherosclerosis | 1135 |
Chagas’ disease | 2197 |
Channelopathy-associated insensitivity to pain | 2390 |
Chaperone | 1685 |
Charcoal-broiled meat | 1685 |
Chemical inhibitors of CYPs | 1455 |
Chemically-induced carcinogenesis | 1598 |
Chemokine (C-C motif) receptor 5-2459 genotype | 1360 |
Chemokine receptor CCR6 | 1135 |
Chemotherapeutics | 2307 |
Chemotherapy-induced anemia | 202 |
Chemotherapy-induced leukemia | 2115 |
Chemotherapy-induced nausea and vomiting | 620, 773 |
Chickenpox | 779 |
Childhood acute lymphoblastic leukemia | 1283, 1598 |
Childhood asthma | 672, 804 |
Childhood leukemia | 2128 |
Chitosan micellar system | 850 |
Chlamydial infection | 147, 167, 168, 248, 276, 340, 700, 709, 731 |
Chlamydophila pneumoniae | 719 |
Chloroquine-resistant Plasmodium falciparum malaria | 616, 633, 638 |
Cholangiocarcinoma | 850, 2092 |
Cholera | 761 |
Cholestasis | 749, 967, 1687, 1916, 2491 |
Cholestatic liver disease | 2400 |
Cholesterol | 823, 929, 996, 1116, 1120, 1161, 1169, 1182, 1187, 1215, 1242, 1687, 1932, 2188, 2245, 2250, 2253, 2300, 2312, 2314, 2337, 2385, 2446, 2465, 2516, 2519 |
Cholesterol 25-hydroxylation activity of CYP3A | 1982 |
Cholesterol efflux pathways | 990 |
Cholesterol gallstone disease | 1916 |
Cholesterol homeostasis in laboratory opossums (Monodelphis domestica) | 1981 |
Cholesterol levels | 1058, 2088 |
Cholesterol metabolism | 817 |
Cholesterol-free mouse | 1916 |
Cholesteryl ester transfer protein (CETP) | 990 |
Cholesteryl oleyl ether | 2385 |
Cholestenoic acid | 1981 |
Cholic acid | 823, 929, 962, 964, 1215, 1687, 1916, 1932, 2019, 2150, 2183, 2194, 2198, 2208, 2217, 2253, 2337, 2446, 2458 |
Cholic and chenodeoxycholic acid | 1233, 1687 |
Choline acetyltransferase | 1135 |
Choline-related organ dysfunction | 2332 |
Chondrogenesis | 850 |
Chorea | 729 |
Choreiform syndrome | 1477 |
Choriocarcinoma | 146, 791, 1004 |
Chorionic gonadotropin | 990 |
Christmas disease | 295 |
Chromomycosis | 407 |
Chromosomal damage | 2498 |
Chromosomal damage and cancer risk | 2527 |
Chromosome 5q deletion syndrome | 1271 |
Chromosome fusion | 1956 |
Chronic alcoholism | 235, 2405 |
Chronic allograft nephropathy | 2455 |
Chronic anal fissure | 90 |
Chronic angina | 645 |
Chronic anterior uveitis | 657 |
Chronic asthma | 732, 801, 804, 1075 |
Chronic bacterial prostatitis | 162 |
Chronic bronchitis | 47, 168, 253, 340, 426, 540, 664, 745, 768 |
Chronic bronchopulmonary disease | 9 |
Chronic constipation | 413, 629, 631 |
Chronic consumptive coagulopathy | 356 |
Chronic diarrhea | 437 |
Chronic eczematous external otitis | 314 |
Chronic granulomatous disease | 390 |
Chronic hepatitis | 1469 |
Chronic hepatitis B virus infection | 12, 413, 718, 723, 2321 |
Chronic hepatitis C | 570, 571, 652, 1598 |
Chronic high-cholesterol diet | 1916 |
Chronic idiopathic constipation | 443, 718 |
Chronic idiopathic pancreatitis | 624 |
Chronic idiopathic urticaria | 54, 142, 211, 425, 438 |
Chronic immune thrombocytopenia | 2197 |
Chronic iron overload | 206 |
Chronic kidney disease | 109, 161, 206, 246, 292, 303, 566, 682, 817, 851, 2247, 2299, 2377 |
Chronic kidney failure | 1031 |
Chronic liver disease | 1489, 1982 |
Chronic lung diseases | 732 |
Chronic lymphocytic leukemia | 18, 71, 146, 167, 190, 311, 380, 540, 578, 661, 851, 2055 |
Chronic mucocutaneous candidiasis | 407 |
Chronic myelocytic leukemia | 190, 195, 367 |
Chronic myelogenous leukemia | 103, 167, 204, 205, 373, 386, 387, 526, 734, 792, 1025 |
Chronic myeloid leukemia | 172, 204, 525, 851, 935, 1004, 1026, 1196,1283, 2429 |
Chronic myeloproliferative disorders | 2331 |
Chronic nonspherocytic hemolytic anemia | 2078 |
Chronic obstructive pulmonary disease (COPD) | 15, 31, 47, 58, 63, 77, 381, 393, 467, 664, 673, 745, 1254, 1266, 1274, 1283, 1309, 1338, 1351, 1598, 2021, 2207, 2247, 2297, 2343, 2527 |
Chronic open-angle glaucoma | 79, 125, 233, 256, 423, 480 |
Chronic pain | 301, 364 |
Chronic pancreatitis | 1056 |
Chronic periodontitis | 2203 |
Chronic plaque psoriasis | 17, 108, 258, 284, 718 |
Chronic Pseudomonas aeruginosa infection in cystic fibrosis | 748, 2056 |
Chronic renal failure | 202, 211, 268, 269, 396 |
Chronic rheumatoid arthritis | 226, 724, 738, 749, 752, 764, 812 |
Chronic rhinitis | 556 |
Chronic rhinosinusitis | 2270 |
Chronic solid organ rejection | 613 |
Chronic stable angina | 5, 34, 86, 229, 403, 523, 788 |
Chronic suppurative otitis media | 540 |
Chronic swelling | 214 |
Chronic synovitis | 2133 |
Chronic thromboembolic pulmonary hypertension | 797, 2138 |
Chronic uremia | 1135 |
Chronic urticaria | 551, 584 |
Circadian regulation | 1916 |
Circadian rhythm sleep disorders | 2289 |
Circulating thymic factor | 2208 |
Cirrhosis | 701, 754, 1688, 2128, 2444 |
Cisplatin-induced renal toxicity | 28 |
Citrobacter rodentium infection | 1598 |
Classic subfoveal choroidal neovascularization | 790 |
Claudin-7-deficiency | 1936 |
Cleft lip/palate | 1220, 2287, 2291 |
Clopidogrel and proton pump inhibitors | 1410 |
Cloning | 1693 |
Clonorchiasis | 612 |
Clubfoot | 1283, 1310 |
Cluster headache | 711, 755 |
Clusterin | 1135 |
c-Myc | 852 |
CNS drugs | 1532 |
CNS-active drugs | 1598 |
CNS infections | 483, 549 |
CNS leukemia/lymphoma | 737 |
CNS metastases | 736 |
CNS pathology-associated risk factors | 1128 |
Coarctation of aorta | 24 |
Cocaine abuse | 2000 |
Cocaine-related disorders | 1258 |
Coccidioides immitis | 39 |
Coccidioidomycosis | 310, 407 |
Cochlea and organ of Corti | 1004 |
Cockayne syndrome (type B) | 2033 |
Cockayne syndrome, photosensitive trichothiodystrophy, and xeroderma pigmentosum/cockayne syndrome complex | 2031 |
Codeine dependence | 1459 |
Coelenterazine- and D-luciferin-based bioluminescence | 852, 935 |
COG112 ApoE-mimetic peptide | 1136 |
Cognition | 1050, 2167, 2170 |
Cognition and prefrontal cortex function | 2099 |
Cognition disorders | 794 |
Cognitive deterioration | 794, 1957 |
Cognitive dysfunction | 794 |
Cognitive function | 675, 1136, 1459, 2009 |
Colchicine resistance | 853 |
Cold stress | 1917 |
Cold-induced CYP1A activation | 1283, 1310 |
Colitis | 1283 |
Collagen diseases | 42, 613 |
Colon adenoma | 1696 |
Colon cancer | 316, 421, 436, 549, 631, 935, 1110, 1211, 1230, 1917, 2192, 2281, 2287, 2361, 2393, 2487, 2518 |
Colon cancer, advanced | 549, 642 |
Colonic evacuation | 680, 694 |
Colonic neoplasms | 964, 1209, 2365, 2483 |
Colorectal adenocarcinoma | 2251 |
Colorectal adenoma | 1383, 1917, 2207 |
Colorectal cancer | 115, 494, 549, 642, 704, 817, 853, 1005, 1054, 1058, 1105, 1113, 1203, 1204, 1211, 1221, 1269, 1283, 1310, 1339, 1459, 1598, 1696, 1957, 1982, 2021, 2029, 2031, 2044, 2084, 2109, 2115, 2119, 2128, 2176, 2188, 2190, 2219, 2225, 2240, 2247, 2271, 2277, 2291, 2294, 2297, 2333, 2341, 2343, 2360, 2369, 2380, 2412, 2415, 2438, 2444, 2448, 2452, 2471, 2480, 2498, 2501, 2515, 2527 |
Colorectal cancer, susceptibility to | 1058, 1269, 2291 |
Colorectal liver metastases | 1696 |
Colorectal polyps | 1095, 2369 |
Colorectal tumor | 642, 1058, 1269, 2291 |
Combined deficiency of vitamin K-dependent clotting factors | 2083 |
Comedications | 1957 |
Common cold | 144, 630, 771 |
Common variable immunodeficiency | 380, 2203 |
Community-acquired pneumonia | 129, 130, 134, 135, 167, 168, 275, 426, 430, 503, 540, 719 |
Comparative studies | 1477, 1481, 1487, 1496, 1502, 1510, 1522, 1523, 1525, 1531, 1550, 1557, 1568, 1578, 1696 |
Complement | 1599 |
Complement C5a inhibitors | 1137 |
Complement receptor 1 (CR1) | 1137 |
Complex absence seizures | 781 |
Complex partial seizures | 781 |
Compulsive craving during alcohol withdrawal | 1957 |
Concurrent primary aldosteronism and subclinical cortisol hypersecretion | 1936 |
Condylomata acuminata | 387, 388 |
Connective tissue-activating peptide | 2323 |
Conformational changes and ligand promiscuity | 1699 |
Congenital adrenal hyperplasia (P450 oxidoreductase deficiency) | 1383, 1459, 1957 |
Congenital afibrinogenemia | 2060 |
Congenital agammaglobulinemia | 380 |
Congenital bilateral absence of the vas deferens | 1247 |
Congenital cardiac disease | 2287 |
Congenital corneal opacification infantile glaucoma and von Hippel’s ulcer | 1339 |
Congenital disorders of glycosylation type I | 2426 |
Congenital glaucoma | 1339 |
Congenital heart disease | 24, 652, 2297 |
Congenital hyperinsulinism | 981, 2233 |
Congenital hypoaldosteronism and sensorineural hearing loss | 1937 |
Congenital myasthenic syndrome associated with episodic apnea | 1249 |
Congenital mysathenic syndromes | 1252 |
Congenital pancreatic hypoplasia and pancreatic agenesis | 982 |
Congenital sucrase-isomaltase deficiency | 671 |
Congestive heart failure | 8, 227, 331, 355, 361, 362, 380, 476, 520, 533, 651, 757, 1068, 1218 |
Congestive heart failure, susceptibility to | 1068 |
Conjunctival congestion | 731 |
Conjunctivitis | 121, 162, 214, 337, 410, 514, 613, 707 |
Constipation | 85, 447, 631, 680 |
Constitutive androstane receptor (CAR) | 854, 1699 |
Contraception | 710 |
Conventional phenotyping | 1506 |
Conversion of cholesterol into bile acids | 1917 |
Convulsive disorders | 220 |
Convulsive states | 332, 734 |
Co-prescription of CYP2D6/3A4 inhibitor-substrate pairs | 1700 |
Corneal edema | 691 |
Corneal epithelium | 1005 |
Corneal injury | 214, 316, 613, 1107 |
Corneal ulcer | 162, 426, 613, 707 |
Coronary arteriosclerosis | 610, 611, 2253 |
Coronary artery aneurysms | 380 |
Coronary artery bypass graft surgery | 610, 611, 739 |
Coronary artery disease (CAD) | 442, 610, 611, 817, 977, 991, 1031, 1048, 1058, 1076, 1110, 1119, 1137, 1371, 1383, 1410, 1599, 1616, 1917, 1925, 2036, 2092, 2109, 2192, 2245, 2256, 2287, 2299, 2325, 2336, 2441 |
Coronary artery disease in familial hypercholesterolemia, protection against | 442, 610, 611, 686 |
Coronary artery disease, autosomal dominant, 1 | 610, 611 |
Coronary artery disease, autosomal dominant, 2 | 610, 611 |
Coronary artery disease, modifier of | 610, 611 |
Coronary artery disease, resistance to | 610, 611 |
Coronary artery disease, susceptibility to | 610, 611, 1076, 2092, 2336 |
Coronary artery stenting | 271, 610 |
Coronary atherosclerosis | 610, 611, 2152, 2225, 2277, 2336 |
Coronary disease | 79, 610, 611, 1117, 1244, 1269, 2049, 2336 |
Coronary heart disease | 339, 610, 611, 686, 1056, 1085, 1090, 1269, 1616, 2176, 2215, 2277, 2287, 2304 |
Coronary heart disease, susceptibility to, 2 | 610, 611 |
Coronary heart disease, susceptibility to, 3 | 610, 611 |
Coronary heart disease, susceptibility to, 4 | 610, 611 |
Coronary heart disease, susceptibility to, 6 | 610, 611 |
Coronary heart disease, susceptibility to, 7 | 610, 611 |
Coronary heart disease, susceptibility to, 8 | 610, 611 |
Coronary heart disease, susceptibility to, 9 | 610, 611 |
Coronary occlusion | 6, 610 |
Coronary restenosis | 610 |
Coronary revascularization | 610 |
Coronary spasm | 610, 611, 2299 |
Coronary spasms, susceptibility to | 610, 611 |
Coronary stenosis | 610, 1137 |
Coronary stent implantation | 610, 740, 1700 |
Coronary thrombosis | 610, 611, 722 |
Coronary vasospasm (coronary spastic angina) | 610, 611, 1137 |
Corpus luteum | 1616 |
Corticobasal degeneration | 1137 |
Corticosteroid-responsive dermatosis | 16, 170, 226, 353, 354, 363, 613 |
Corticosterone methyloxidase deficiency | 1937 |
Corynebacterium infections | 337 |
Cough | 219, 249, 351, 362, 393 |
Coumarin 7-hydroxylation | 1351 |
Coumarin resistance | 2521 |
Courtship behavior | 1957 |
CpG methylation | 1311 |
CpG ODN 2006 | 2184, 2208, 2217, 2446, 2458 |
CPG-oligonucleotide | 2371 |
C-Reactive protein | 1937 |
Cramps | 60, 780 |
Craniocerebral trauma | 141 |
Creutzfeldt-Jakob disease | 1137, 2349 |
Cri-du-chat syndrome | 2441 |
Crigler-Najjar’s syndrome | 2487, 2496 |
CRIM1 | 855 |
Crohn’s disease | 11, 97, 141, 384, 514, 732, 855, 1085, 1225, 1258, 1271, 1274, 1701, 1907, 2058, 2207, 2215, 2219, 2311, 2362, 2452, 2466 |
Crohn’s disease-associated growth failure | 2207 |
Cryopreserved human hepatocytes | 1701 |
Cryopyrin-associated periodic syndromes | 113, 656 |
Cryptococcal meningitis | 310 |
Cryptococcus neoformans | 39 |
Cryptorchidism | 1185 |
CUGBP2 | 1137 |
Cushing’s syndrome | 30, 214, 1702 |
Cutaneous and mucosal leishmaniasis | 2212 |
Cutaneous candidiasis | 158, 177, 256, 407, 538 |
Cutaneous dermatophytoses | 407, 610, 613 |
Cutaneous drug-metabolizing enzymes | 1402 |
Cutaneous larva migrans | 733 |
Cutaneous leishmaniasis | 2452 |
Cutaneous malignant melanoma | 1204, 1235 |
Cutaneous melanoma | 2515 |
Cutaneous T-cell lymphoma | 208, 608, 664, 796 |
Cutaneous/gastrointestinal/oropharyngeal anthrax | 426 |
CXCL16 | 1138 |
CXCRs | 1005 |
Cyanide poisoning | 41, 366, 477, 695 |
Cyclic AMP | 1247, 1259, 2150, 2154, 2155, 2194, 2220, 2346 |
Cyclic GMP | 967, 971, 1088, 1106, 2300, 2305, 2371, 2458 |
Cyclin D1 | 1957 |
Cyclin-dependent kinase 2 | 1702 |
Cyclin-dependent kinase inhibitors | 855, 1702 |
Cyclooxygenase-2 | 856, 1005 |
Cyclooxygenases (COX-1, COX-2) | 968 |
Cyclophosphamide in breast cancer | 1360 |
Cyclophosphamide in lupus nephritis | 1361 |
Cycloplegia | 59, 190 |
CYP induction | 1361 |
CYP inhibitors | 1412, 1460, 1599, 1712 |
CYP phosphorylation | 1712 |
CYP17 inhibitors | 1712 |
CYP1A1 expression | 1284 |
Cyp1a1-Ren-2 transgenic rats | 1284 |
CYP1A2 induction | 1311 |
CYP1A2 metabolism screening | 1311 |
Cyp2a5-null mouse | 1351 |
CYP2A6 variants | 1351 |
CYP2A13 and lung cancer | 1352 |
CYP2C induction | 1403 |
CYP2C P450 enzymes in human hepatocytes | 1705 |
CYP2C18-19 humanized mice | 1402 |
CYP2D6 and antidepressant switching | 1445 |
CYP2D6 in Alzheimer’s disease | 1442 |
CYP2D6-CYPOR | 1460 |
CYP2D6-NADPH cytochrome P450 reductase fusion protein | 1705 |
CYP2D6-related biochemical and hemodynamic phenotypes in Alzheimer’s disease | 1442 |
CYP2D6-related therapeutic response to a multifactorial treatment | 1442 |
CYP2J2 inhibitors | 1616 |
CYP2J2 substrates | 1617 |
CYP3A cluster (CYP3A4, CYP3A5, CYP3A7, CYP3A43) | 1705 |
CYP3A isozyme ligands | 1708 |
CYP3A4 5′ promoter variants | 1709 |
CYP3A4 5′ regulatory region | 1707 |
CYP3A4 catalytic specificity | 1705 |
CYP3A4 degradation | 1706 |
CYP3A4 induction | 1708 |
CYP3A4 inhibitors | 1708 |
CYP3A4 multiple substrate binding | 1709 |
CYP3A4 oxidation | 1709 |
CYP3A4 transactivation | 1710 |
CYP3A4 vs CYP3A5 | 1706 |
CYP3A4*20 (CYP3A4 allele without functional activity) | 1706 |
CYP3A4/5/7 gene expression | 1707 |
CYP3A4/5/7 gene expression in cancer | 1707 |
CYP3A4-ABCB1 (MDR1) interactions | 1708 |
CYP3A4-CYP2C8 interactions | 1706 |
CYP3A4-CYP2D6 interactions in psychiatric patients | 1706 |
CYP3A4-PXR relationship | 2311 |
CYP3A4-UDP-glucuronosyltransferase activity | 1710 |
Cys11-Cys15-endothelin-1 (11-21) | 2013 |
Cystic fibrosis | 9, 242, 748, 935, 1247, 1460, 1712, 2192, 2444 |
Cystic fibrosis lung transplant | 1412 |
Cystic fibrosis pulmonary disease | 2014 |
Cystic hydatid disease | 14 |
Cystic tumors | 764 |
Cysticercosis | 612 |
Cystine-based glutathion precursor (F1 antioxidant) | 1138 |
Cystinuria | 574 |
Cystitis | 162, 307 |
Cytochrome b5 | 1460, 1713 |
Cytochrome C oxidase deficiency | 2281 |
Cytochrome P450 1A1 gene transcription | 2109 |
Cytochrome P450 oxidoreductase | 1312, 1460, 1957 |
Cytochrome P450 oxidoreductase deficiency | 1957 |
Cytochrome P450 oxidoreductase deficiency and Antley-Bixler craniosynostosis syndrome | 1957 |
Cytochrome P450 reductase | 1713 |
Cytochrome P450 time-dependent inhibition assays | 1713 |
Cytokine-induced killer (CIK) cell | 856 |
Cytomegalovirus | 818 |
Cytomegalovirus disease | 195, 780 |
Cytomegalovirus infections | 336, 780 |
Cytomegalovirus retinitis | 158, 330, 336, 780 |
Cytokines | 936, 1403, 1713 |
Cytotoxic ribonuclease PE5 | 857 |
D | |
Dandruff | 179, 407, 672, 679 |
Dap1/PGRMC1 | 1624, 1714 |
de novo Acute leukemia | 1006 |
De Sanctis-Cacchione syndrome | 2033 |
Death | 1524 |
Decreased viability among fetuses | 2287 |
Deep venous thrombosis | 199, 327, 703, 744, 797, 1384, 2048, 2299 |
Defective control of prolactin secretion | 628 |
Defective CYP3A4 and CYP3A5 SNPs | 1715 |
Deficiencies of carbamoylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase | 693 |
Deficiency of the prothrombin complex coagulation factors II, VII, IX, and X | 628 |
Degenerative disc disorder | 2081 |
Degree of CYP450 enzyme inhibition of antidepressant drugs at their usual therapeutic dose | 1444 |
Dehydration | 220 |
Delayed male puberty | 728 |
Delayed puberty | 349 |
Delayed sleep phase syndrome | 1273 |
Delirium | 301, 589, 1138 |
Delta-storage pool deficiencies | 968 |
Dementia | 277, 662, 713, 750, 1170 |
Dementia of the Alzheimer’s type | 662, 713, 750, 1170 |
Dementia syndromes | 342 |
Demyelinating diseases | 380 |
Dengue disease | 2130, 2438 |
Dengue hemorrhagic fever | 2444 |
Dental caries | 315 |
Dental expression | 1006 |
Dental pain | 321 |
Depression | 33, 37, 165, 210, 245, 378, 396, 450, 485, 493, 497, 516, 537, 583, 609, 629, 702, 710, 762, 770, 791, 857, 1138, 1263, 1265, 1266, 1412, 1461, 2062, 2092, 2162, 2163, 2287, 2369, 2395, 2396, 2417, 2520 |
Depressive disorder | 609, 648, 1266, 2165 |
Depressive emotional conditions | 342 |
Dermatitis | 314, 672 |
Dermatitis herpetiformis | 201 |
Dermatologic diseases | 613, 764 |
Dermatophytes | 725, 776 |
Dermatophytoses | 35, 177, 256 |
Dermatosis | 212, 217, 322, 350, 407, 499 |
Des-Arg9-Bradykinin | 2459 |
Desmoid disease | 1113 |
Desmoid tumor | 791 |
Dexmedetomidine anesthesia | 959, 1066, 1930 |
Developmental changes | 1461 |
Developmental delay, epilepsy and neonatal diabetes syndrome | 2233 |
Deviant anti-social sexual behavior | 71 |
Diabetes | 631, 936, 1372, 1958, 1983, 2197, 2261, 2339 |
Diabetes and food intake | 1477 |
Diabetes and insulin resistance syndrome | 2343 |
Diabetes insipidus | 211, 785 |
Diabetes mellitus | 79, 610, 818, 982, 991, 1076, 1081, 1117, 1138, 1214, 1240, 1269, 1384, 1462, 1617, 1718, 2037, 2211, 2235, 2281, 2415, 2483, 2501 |
Diabetes mellitus (type 1 and type 2) | 1226 |
Diabetes mellitus (type 1) | 385, 610, 1049, 1058, 1233, 2130, 2134, 2138, 2140, 2143, 2180, 2219, 2299, 2445 |
Diabetes mellitus (type 2) | 293, 344, 345, 346, 394, 610, 649, 667, 676, 689, 1066, 1076, 1081, 1086, 1235, 1269, 2053, 2088, 2093, 2101, 2248, 2290, 2478, 2529 |
Diabetes mellitus, insulin-dependent | 610 |
Diabetes mellitus, noninsulin-dependent | 4, 610, 649, 667, 676, 689, 750, 751 |
Diabetes, susceptibility to | 2290 |
Diabetic gastric stasis | 481 |
Diabetic gastroparesis | 240 |
Diabetic ketoacidosis | 385 |
Diabetic macrovascular disease (type 1) | 1983 |
Diabetic nephropathy | 117, 252, 394, 441, 636, 1086, 1138, 1983, 2109, 2192, 2235, 2346, 2422 |
Diabetic nephropathy (type 2) | 636, 2215 |
Diabetic neuralgia | 118 |
Diabetic neuropathic ulcers | 68 |
Diabetic neuropathy | 116, 615 |
Diabetic retinopathy | 2336, 2346 |
Diabetic vascular disease | 2153 |
Diagnostic procedures | 773 |
Diagnostic test | 775, 785 |
Diaper rash | 144, 805 |
Diarrhea | 60, 86, 144, 155, 412, 480, 519, 529, 565, 601, 671 |
Diarrhea-predominant irritable bowel syndrome | 22, 1066 |
Diazoxide-responsive hyperinsulinemic hypoglycemia | 982, 2149 |
Dicer-related liver zonation | 1599 |
Diet | 1720 |
Dietary factors | 1720 |
Dietary fiber supplement | 631 |
Dietary rice protein | 1139 |
Dietary sodium intake | 1937 |
Dietary supplement | 111, 112, 113, 145, 154, 446, 447, 750, 795, 1139 |
Diffuse large B-cell CD20-positive NHL | 661, 757 |
Diffuse large B-cell lymphoma | 2528 |
Diffuse panbronchiolitis | 1720 |
Dihydropyrimidinase deficiency | 1996 |
Dihydropyrimidine dehydrogenase deficiency | 1995 |
Dihydrotestosterone (DHT) | 1027, 1098, 1099, 1102, 1103, 1161, 1182, 1187, 1194, 1220, 1222, 1233, 1978, 2040, 2072, 2177, 2188, 2253, 2312, 2345, 2352, 2376, 2446, 2453, 2459, 2519 |
Dilated cardiomyopathy | 1068, 1071, 1073, 2354, 2358 |
Diphtheria | 255, 276 |
Discoid lupus erythematosus | 732, 764 |
Disinfection of utensils and equipment | 692 |
Disseminated candidiasis | 310 |
Distal hereditary motor neuropathy | 1193 |
Distal interphalangeal joint osteoarthritis | 2192 |
Distal myopathy | 2334 |
Diuretic non-responders with non-azotemic cirrhosis and ascites | 1937 |
Diverticulitis | 677 |
Dizziness | 255 |
DNA hypomethylation | 983 |
DNA methylation and Epigenetic phenomena | 859 |
DNA microarray technology | 1723 |
DNA repair | 1600 |
Dominant beta-thalassemia inclusion body type | 2125 |
Dopa-responsive dystonia | 2081 |
Double-transduced MDCKII Cells | 861 |
Down’s syndrome | 991, 1170, 2287, 2291 |
Doxorubicin and cyclophosphamide in breast cancer | 1361 |
Doxycycline-inducible, tissue-specific aromatase-expressing transgenic mouse | 1958 |
Dracunculiasis | 733 |
Drinking behavior | 1600 |
Drug addictions | 166 |
Drug biotransformation | 1725 |
Drug disposition | 1007 |
Drug oxidation | 1464 |
Drug transporters and phase I and II metabolism | 1725 |
Drug-associated torsades de pointes, LQTS and arrhythmia | 2229, 2231 |
Drug-induced extrapyramidal symptoms | 26, 621, 767 |
Drug-induced liver injury | 1385, 1725 |
Drug-induced methemoglobinemia | 477 |
Drug-induced osteoporosis | 1958 |
Drug-induced torsade de pointes | 2231 |
Drug-resistant tuberculosis | 286 |
Drugs of abuse | 1007 |
Drug-virus interaction | 1725 |
Dry eye syndrome | 367 |
Ductal carcinoma | 715 |
Ductus arteriosus | 24, 383 |
Duodenal ulcer | 160, 279, 296, 415, 534, 545, 640, 645, 706, 710 |
Dutch familial combined hyperlipidemia | 2466 |
Dynamic equines foot deformity | 90 |
Dysfunctional uterine bleeding | 349 |
Dyskeratosis congenita | 2441 |
Dyslipidemia | 57, 299, 522, 597, 675, 1726, 1918, 2052, 2054, 2292 |
Dysmenorrhea | 5, 265, 371, 455, 780 |
Dysphagia | 399 |
Dysprothrombinemia | 2048 |
Dysuria | 307 |
E | |
E. coli infection | 39, 119, 128, 594 |
Early-onset diabetes (type 2) | 1251 |
Eating disorders | 1465, 2167 |
Eclampsia | 449 |
Ecto-5′-nucleotidase and thiopurine | 968 |
Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) | 1139 |
Ectopic calcification | 287 |
Eczema | 255 |
Edema | 8, 98, 150, 153, 285, 333, 362, 381, 476, 613, 701, 2377 |
Edematous states | 29, 613 |
Efferocytosis | 818 |
Ehlers-Danlos syndrome | 1261 |
Ehrlichiosis | 1727 |
Elderly | 1535, 1558 |
Electrolyte replacement | 448 |
Electrolytes | 1248 |
Embolism | 356, 797 |
Embryonic carcinoma | 1007 |
Emergency contraception | 427 |
Emetogenic cancer chemotherapy | 46 |
Emphysema | 47, 253, 393, 745, 1904, 2021 |
Empiric antifungal therapy | 795 |
Endobronchial non-small cell lung cancer | 1968 |
Endocarditis | 309, 310, 341, 377, 704 |
Endocrine disorders | 613, 764 |
Endoglin | 1139 |
Endometrial cancer | 190, 456, 1285, 1314, 1335, 1728, 1958, 2023, 2044, 2432 |
Endometrial hyperplasia | 456, 621 |
Endometrioid adenocarcinomas | 1045 |
Endometriosis | 101, 200, 349, 422, 508, 535, 864, 1095, 1412, 1958, 1965, 1983, 2156, 2176, 2518 |
Endometriosis-associated pain | 456 |
Endoscopic retrograde cholangiopancreatography visualization | 678 |
Endothelial nitric oxide synthase | 1340 |
Endothelin-1 | 991 |
Endothelin-1 receptor antagonists | 864 |
Endotracheal intubation | 58, 164, 646, 663, 705 |
End-stage renal disease | 416, 1937, 2037 |
Engraftment syndrome | 1007 |
Enteric fever | 1247 |
Enteric rods | 162 |
Enteritis | 769 |
Enterobacter infection | 39, 119 |
Enterocutaneous and rectovaginal fistulas | 384 |
Enuresis | 211, 265 |
Enzyme kinetics | 1729 |
Ependymoma | 124, 864, 1007 |
Epicondylitis | 764 |
Epidermal growth factor receptor 2-positive metastatic breast cancer | 760, 1959 |
Epidermal nevus | 2240, 2333 |
Epidermis | 1959 |
Epidermophyton infections | 725 |
Epigenetics | 1340, 1729, 1959 |
Epilepsy | 170, 220, 333, 463, 808, 864, 1140, 1253, 1285, 1385, 1413, 1465, 1729, 2349, 2385, 2386, 2387, 2467 |
Epilepsy with generalized tonic-clonic seizures | 220, 584, 588 |
Epilepsy with grand mal seizures on awakening | 617 |
Epilepsy, generalized idiopathic | 1253 |
Epilepsy, juvenile myoclonic | 1253 |
Epileptic seizures | 118 |
Episcleritis | 457 |
Episiotomies | 798 |
Epithelial keratitis | 767 |
Epithelial ovarian cancer, somatic | 460 |
Erectile dysfunction | 24, 684, 715, 783, 1730, 2092, 2299 |
ERK1 and ERK2 MAPKs | 1314 |
Erosive esophagitis | 279, 415, 545, 645, 1413, 1420 |
Erythema multiforme | 732 |
Erythema nodosum leprous | 732 |
Erythrasma | 276 |
Erythromycin breath test | 1731 |
Erythropoietic protoporphyria | 77 |
Escherichia coli infection | 39, 119, 128, 594 |
Esophageal achalasia | 90 |
Esophageal adenocarcinoma | 1959 |
Esophageal cancer | 603, 866, 1007, 1054, 1105, 1240, 1386, 1600, 2115, 2130, 2134, 2369, 2471, 2518 |
Esophageal candidiasis | 310, 486, 795 |
Esophageal mucosa and nitrosamine metabolism | 1732 |
Esophageal spasms | 399 |
Esophageal squamous cell carcinoma | 1352, 1732 |
Esophageal varices | 696, 785 |
Esophagitis | 215, 296 |
Essential fatty acid deficiency | 699, 1919 |
Essential hypertension | 114, 229, 612, 626, 636, 643, 650, 701, 720, 725, 742, 757, 758, 765, 782, 788, 1035, 1063, 1066, 1068, 1071, 1077, 1081, 1197, 1937, 2007, 2023, 2093, 2143, 2380, 2415 |
Essential tremor | 617, 626, 2003 |
Estradiol deficiency | 1959 |
Estrogen receptor alpha | 1413 |
Estrogen receptor beta modulator 8β-VE2 | 1140 |
Estrogen receptor beta signaling | 1007 |
Estrogen receptor mutant (temperature-sensitive) | 2037 |
Estrogen receptor mutations | 1960 |
Estrogen receptor-positive breast cancer | 756, 1960 |
Estrogen replacement therapy | 1140 |
Estrogen resistance | 2037 |
Estrogen-related receptor gamma (ERRG) | 1960 |
Estrous cycle | 1600 |
Ethanol dependence | 510 |
Ethanol metabolism | 1107 |
Ethanol withdrawal | 220, 552 |
Ethnic differences | 866, 936, 968, 978, 1008, 1140, 1286, 1314, 1352, 1362, 1373, 1386, 1403, 1413, 1471, 1601, 1618, 1734, 1960 |
Euvolemic and hypervolemic hyponatremia | 184, 754 |
Evacuation of bowel | 680, 694 |
Evolution of CYP3A4 expression variability | 1739 |
Ewing’s sarcoma | 190, 198, 867, 1008 |
Ex3α ERKO male infertility | 1960 |
Excitability | 359, 702, 780 |
Exercise-induced asthma | 2257 |
Exercise-induced bronchospasm | 187, 673 |
Exercise training | 2346 |
Exfoliation glaucoma | 2251 |
Exogenous obesity | 74, 225, 470 |
Experimental autoimmune neuritis | 1142 |
Experimental colitis | 1919 |
Experimental venous thrombosis | 1938 |
Extensive metabolizers (EMs) | 1506 |
External genital and perianal warts secondary to Condylomata acuminate | 687 |
Extra-adrenal 21-hydroxylation | 1739 |
Extraintestinal amebiasis | 149 |
Extrapyramidal side-effects | 1549 |
Extrapyramidal symptoms | 1488 |
Eye irritations | 276 |
F | |
Fabry disease | 13 |
Facial dermatoses | 613 |
Facial lipoatrophy | 601 |
Facial mottled hyper-/hypopigmentation | 718 |
Facial skin wrinkling | 718 |
Factor V deficiency | 2049 |
Factor VII deficiency | 295, 2051 |
Factor IX deficiency | 295 |
Fallot’s tetralogy | 24 |
Familial adenomatous polyposis | 139, 1113, 2068 |
Familial Alzheimer’s disease | 1165, 2263, 2355, 2358 |
Familial atrial fibrillation | 2235 |
Familial atrial fibrillation 3 | 2235 |
Familial atrial fibrillation 4 | 2230 |
Familial atrial fibrillation 6 | 2305 |
Familial cold autoinflammatory syndrome | 113, 656 |
Familial combined hyperlipidemia | 2054 |
Familial dysbetalipoproteinemia | 611, 1132 |
Familial febrile convulsions, 3 | 2385 |
Familial hemiplegic migraine-3 | 2386 |
Familial hyperaldosteronism | 1938 |
Familial hyperaldosteronism type 1 | 1938 |
Familial hypercholesterolemia | 611, 686, 818, 991, 1119, 2245 |
Familial hyperinsulinemic hypoglycemia 1 | 983 |
Familial hyperinsulinemic hypoglycemia 2 | 2233 |
Familial hyperinsulinism | 983 |
Familial hyperproreninemia | 2377 |
Familial hypertriglyceridemia | 611 |
Familial hypobetalipoproteinemia | 1119 |
Familial hypocalciuric hypercalcemia | 1212 |
Familial juvenile glaucoma | 1341 |
Familial male-limited precocious puberty (testotoxicosis) | 1961 |
Familial Mediterranean fever | 181 |
Familial medullary thyroid carcinoma | 2379 |
Familial melanoma | 619 |
Familial mild hyperglycemia | 983 |
Familial partial lipodystrophy (type 3) | 2343 |
Familial/Primary hyperaldosteronism type I | 1938 |
Fanconi’s anemia | 1209 |
Fas receptor | 1739 |
Fatal familial insomnia | 2349 |
Fatigue | 343 |
Fatty acid metabolism and metabolic diseases | 1908 |
Fatty liver (Hepatic steatosis) | 1120, 1489, 2292, 2311 |
Favism | 2077 |
Febrile granulocytopenic patients | 135 |
Febrile neutropenia | 126, 131, 162 |
Febrile seizures | 2385 |
Female genital neoplasm | 2432 |
Female infertility | 326, 462 |
Fertility | 1140 |
Fertility status in endometriosis | 1961 |
Fetal alcohol syndrome | 1054 |
Fetal and newborn complications | 1535 |
Fetal drug exposure | 868 |
Fetal hydantoin syndrome | 2021 |
Fetal tissues | 1618 |
Feto-placental unit | 1741 |
Fetoprotection | 1008 |
Fever | 7, 53, 234, 371, 673 |
Fibrillation | 372 |
Fibrinogen plasma levels | 2060 |
Fibrinolysis | 30 |
Fibroblast growth factor 15/19 | 1919 |
Fibroblast growth factor receptor 4 | 1920 |
Fibrocystic breast disease | 200 |
Fibroids | 600 |
Fibrolamellar hepatocellular carcinoma | 1961 |
Fibromyalgia | 251, 490, 615, 1141, 1263 |
Fibrosarcoma | 196 |
Fibrositis | 702 |
Fibrotic and inflammatory lung diseases | 1601 |
Fibrous dysplasia | 2071 |
First-pass hepatic and intestinal biotransformation | 1742 |
FK506-binding protein | 1742 |
Flinders sensitive line rat model of depression | 1315 |
FLT3-Internal tandem duplication | 2063 |
Flucloxacillin-induced liver injury | 2126 |
Fluorouracil resistance | 1114 |
Flutter | 618, 626, 637 |
Focal segmental glomerulosclerosis | 1938 |
Folate homeostasis | 1745 |
Follicular carcinoma of the thyroid gland | 1993 |
Follicular non-Hodgkin lymphoma | 370, 387, 757 |
Folliculitis | 309 |
Food consumption | 2396 |
Food intake | 1141 |
Food-drug interactions | 1745 |
Forensic toxicology | 1746 |
Forkhead box transcription factor O1 | 1920 |
Fragile X syndrome | 2069 |
Fragile X-associated tremor/ataxia syndrome | 2069 |
Fredrickson type IIa, IIb, and IV hyperlipidemias | 182, 667 |
Fredrickson type III hyperlipidemia | 667 |
Freezing human liver microsomes | 1746 |
Friedreich’s ataxia | 373 |
Frontotemporal dementia | 2349, 2356 |
Frontotemporal dementia with parkinsonism linked to chromosome 17 | 2264 |
Frontotemporal lobar degeneration | 1141 |
Fuchs uveitis | 2176 |
Functional bowel disorders | 70 |
Functional disorders of the biliary tract | 592 |
Functional dyspepsia | 2478 |
Functional indigestion | 562 |
Fungal infection | 39, 126, 177, 310, 402, 514, 707, 763, 795 |
Fungal peritonitis | 39 |
Furuncles | 287 |
G | |
Galactorrhea | 434 |
Gallbladder bile sampling | 687 |
Gallbladder cancer | 1009, 1226, 1286, 1920, 2369 |
Gallbladder stone disease | 145, 1920 |
Gallbladder stone dissolution | 778 |
Gallstone disease | 2487 |
Gallstone formation | 1920 |
Gardner’s syndrome | 1114 |
Gardnerella vaginalis | 743 |
Gastric adenocarcinoma | 237 |
Gastric antacids | 1469 |
Gastric cancer | 247, 870, 937, 968, 1009, 1095, 1114, 1240, 1316, 1341, 1484, 1602, 2025, 2090, 2105, 2109, 2219, 2270, 2275, 2287, 2297, 2307, 2369, 2412, 2422, 2480, 2518, 2526, 2528 |
Gastric cancer and Helicobacter pylori | 2192, 2197 |
Gastric cardiac adenocarcinoma | 2445, 2526 |
Gastric expression | 1484 |
Gastric hyperacidity | 691 |
Gastric hypersecretory states | 160, 640 |
Gastric tumors | 1747 |
Gastric ulcer | 160, 279, 494, 534, 545, 645 |
Gastrinoma | 539, 678 |
Gastroenteritis | 276 |
Gastroesophageal reflux diseases | 160, 163, 215, 279, 296, 415, 481, 534, 545, 564, 640, 645, 1414, 2197 |
Gastrointestinal cancer | 1602 |
Gastrointestinal complications | 160 |
Gastrointestinal diseases | 613, 763 |
Gastrointestinal hypersecretory disorders | 640 |
Gastrointestinal infections | 140 |
Gastrointestinal prokinetics | 1748 |
Gastrointestinal side-effects | 1483 |
Gastrointestinal stromal tumor | 376, 712, 2238, 2331 |
Gastrointestinal tract | 66 |
Gastroparesis | 163 |
Gastroschisis | 2434 |
GATA4 deficiency | 1962 |
Gaucher’s disease | 1032 |
Gaucher’s disease (type 1) | 20, 377, 490 |
Gender | 872, 1469, 1921 |
Gender-related differences | 1316, 1485, 1962 |
Gene interactions | 1141 |
Gene silencing | 1142 |
General anesthesia | 397, 472, 487, 496, 563, 593, 622, 624, 646, 648, 663, 682, 705, 706, 734, 786 |
Generalized aggressive periodontitis | 2197 |
Generalized anxiety disorder | 567, 787, 1447 |
Generalized epilepsy with febrile seizures plus 2 | 2386 |
Generalized epilepsy with febrile seizures plus, type 7 | 2390 |
Generalized tonic-clonic seizures (grand mal) | 118, 617 |
Generalized tonic-clonic (grand mal), complex partial seizures | 617 |
Genetic markers for antidepressant medication intolerance | 1535 |
Genetic predictors of inter-individual variability | 1748 |
Genetic variation in the human AS3MT gene | 1191 |
Genital and perianal warts | 379, 687 |
Genital herpes | 10, 779 |
Genital infections | 129 |
Genital warts | 359, 388, 600 |
Genitourinary irrigant | 698 |
Genitourinary tract infections | 140, 536 |
Genomic index of sensitivity to endocrine therapy | 1962 |
Genomic instability | 1010 |
Germ cell tumor | 88, 2238 |
Germline genetic variation | 1485 |
Gerstmann-Sträussler disease | 2349 |
Gestational diabetes mellitus | 1962, 2149, 2190, 2235 |
Gestational hypertension | 1938 |
Gestational trophoblastic neoplasm | 198 |
GGN repeat polymorphisms | 1185 |
GH stimulation | 680 |
Ghosal hematodiaphyseal dysplasia syndrome | 2440 |
GI hemorrhage | 785 |
Giardiasis | 743 |
Gilbert’s syndrome | 2487, 2494, 2496, 2499 |
Gingival hyperplasia | 1749 |
Gingivitis | 119, 255 |
Gitelman syndrome | 2402 |
Glanzmann thrombasthenia | 2226 |
Glaucoma | 8, 117, 166, 590, 742, 1077, 1090, 1142, 2287 |
Glaucoma surgery | 624 |
Glioblastoma | 937, 1010, 1235, 1240, 1750, 2025, 2115, 2120, 2203, 2270, 2271, 2333, 2471 |
Glioblastoma multiforme | 124, 721, 1002, 2343 |
Glioma | 872, 978, 1002, 1010, 1045, 1231, 1962, 2441 |
Glucocorticoid receptor | 1750 |
Glucocorticoid resistance | 2316 |
Glucocorticoid-induced hypertension | 2249 |
Glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia | 1750 |
Glucocorticoid-induced osteoporosis | 18, 657 |
Glucocorticoid-remediable aldosteronism | 1938 |
Glucose homeostasis | 2343 |
Glucose metabolism | 2052 |
Glucose-6-phosphate dehydrogenase deficiency | 2077 |
Glucosylceramide synthase | 872 |
Glucuronic acid epimerase | 1142 |
Glucuronidation | 1750 |
Glutathione synthetase deficiency | 2103 |
Glutathione synthetase deficiency of erythrocytes | 2103 |
Glutathione transferases (GSTs) superfamily | 2107 |
Gonadal ontogeny | 1962 |
Gonorrhea | 134, 137, 138, 536, 540, 574, 700, 731 |
Goose fatty liver | 1921 |
Gout | 53, 572, 2259, 2445 |
Gouty arthritis | 21, 617, 709, 764 |
GP88 (PC-Cell derived growth factor, Progranulin) | 1962 |
gp120 binding B40 aptamer | 1751 |
Graft vs host disease | 732, 795, 2143 |
Gram-negative bacterial infection | 29, 63, 183, 377, 731, 740, 747, 748, 2452 |
Gram-negative organisms | 731, 747 |
Gram-positive organisms | 65, 377, 731 |
Grand mal | 617 |
Granulocytic leukemia | 734 |
Granuloma annulare lesions | 764 |
Graves disease, susceptibility to | 1077, 2090 |
Graves’ disease | 1077, 1274, 1991, 2090, 2130, 2176, 2203, 2207, 2224, 2287 |
Graves’ ophthalmopathy | 991 |
Graves-Basedow disease | 873 |
GRF test | 680 |
Group X secretory phospholipase A2 | 818, 992 |
Growth failure | 697 |
Growth hormone | 1486 |
Growth hormone deficiency | 175, 697 |
Growth hormone secreting pituitary tumors | 2090 |
Guanosine triphosphate | 1010, 2154 |
Guillain-Barré syndrome | 1142, 2058 |
Guillain-Barré syndrome and experimental autoimmune neuritis | 1142 |
Gut microbes | 874 |
Gynecologic cancers | 1983 |
Gynecologic infections | 132, 133, 137, 377, 740 |
H | |
Haemophilus influenzae type b infection | 39, 63, 134, 337, 353, 654, 2215 |
Hair and skin pigmentation | 2267 |
Hair growth | 1963 |
Hairy cell leukemia | 167, 386, 387,578 |
Haloperidol pyridinium neurotoxicity | 1488 |
Hand dermatoses | 613 |
Hand-foot syndrome | 1243 |
HAP1 (Huntingtin-associated protein 1)(17q21.2-q21.3) | 2173 |
HAPIP (Huntingtin-associated protein-interacting protein) | 2173 |
Haptoglobin | 1142 |
Hashimoto’s thyroiditis | 1274, 2439 |
Hay fever | 304 |
HBV infection | 1755 |
HDL (reconsitituted) | 1142 |
HDL-Cholesterol | 818, 824, 1161, 1244, 2037, 2044, 2338, 2385, 2460 |
HDL cholesteryl ester | 2385 |
Head and neck cancer | 28, 316, 792, 1010, 1056, 1286, 1415, 1619, 2294, 2471, 2488, 2499 |
Head and neck squamous cell carcinoma | 1317, 1341, 1389, 1602, 2291, 2307, 2380, 2412, 2442, 2445 |
Head lice | 449 |
Headache | 144, 228, 342, 1755 |
Hearing disorders | 791 |
Heart | 1010 |
Heart CYP expression | 1619 |
Heart failure | 79, 86, 114, 117, 125, 153, 158, 261, 355, 433, 491, 636, 754, 758, 782, 1071,1939, 2098, 2228 |
Heart transplant | 714, 780, 874 |
Heart, kidney, or liver transplant recipients | 713 |
Heartburn | 296 |
Heat shock proteins (HSP60, HSP72, HSP90, and HSC70) | 1010 |
Heavy metal detoxification | 937 |
Hedgehog signaling | 874 |
Heinz body anemias | 2125 |
Helicobacter pylori infection | 38, 86, 415, 545, 640, 645, 731, 1415, 1416, 1756, 2199, 2343 |
Helicobacter pylori-related chronic gastritis/gastric ulcer | 415, 874 |
Helminthic infections | 733 |
Hematologic diseases | 613, 764 |
Hematologic malignant diseases | 1619 |
Hematopoietic stem cell proliferation | 819 |
Hematopoietic stem cell transplantation | 2287 |
Heme | 1010, 1182, 2054, 2446 |
Heme oxygenase-1 | 1317, 1603 |
Hemiballismus | 729 |
Hemodialysis | 682, 1756 |
Hemoglobinopathies | 2125 |
Hemolytic anemia due to glutathione synthetase deficiency | 2103 |
Hemolytic-uremic syndrome | 1245 |
Hemophilia | 295, 759 |
Hemophilia A | 43, 44, 211, 295 |
Hemophilia B | 43, 295 |
Hemorrhage | 266 |
Hemorrhagic shock | 1389, 1489 |
Hemorrhoids | 73, 221, 255, 610, 798 |
Hemostasis | 183, 737 |
Heparin overdosage | 627 |
Heparin-induced thrombocytopenia | 48 |
Hepatic cirrhosis | 29, 285, 333 |
Hepatic coma | 566 |
Hepatic drug transport | 2409 |
Hepatic encephalopathy | 519 |
Hepatic ischemia-reperfusion injury | 1603 |
Hepatic lipase deficiency | 2250 |
Hepatic steatosis | 675, 1756, 1787 |
Hepatic steatosis and acetaminophen hepatotoxicity | 1469 |
Hepatic venocclusive disease | 2105 |
Hepatitis | 1603, 1756 |
Hepatitis A | 357, 379 |
Hepatitis B | 387, 1142, 1226, 2138, 2143 |
Hepatitis B and hepatocellular carcinoma | 2215 |
Hepatitis B infection | 2037 |
Hepatitis C | 386, 387, 388, 1142, 1226, 1489, 2143, 2179, 2182 |
Hepatitis C virus protease inhibitor S5 | 874 |
Hepatoblastoma | 874, 937, 1114 |
Hepatocarcinoma | 874 |
Hepatocellular carcinoma | 929, 1011, 1114, 1218, 1267, 1317, 1603, 1908, 1921, 2037, 2115, 2144, 2369, 2471, 2499 |
Hepatocellular carcinoma (childhood type) | 2270 |
Hepatocellular tumors | 1756, 2240 |
Hepatocyte growth factor | 1363, 1756 |
Hepatocyte nuclear factor 1 alpha | 1922 |
Hepatocyte nuclear factor 3 gamma | 1403 |
Hepatocyte nuclear factor 4 alpha | 1373, 1757 |
Hepatocyte transplantation | 875, 1603 |
Hepato-intestinal metabolic activity | 1489 |
Hepatoma cell line H4IIE | 1287 |
Hepatoma cells | 1757 |
Hepatoma multidrug resistant cell line SK-Hep-1 | 937 |
Hepatotoxicity | 1489, 1569, 2294 |
Hepatotrophic factor | 1757 |
Herbal bioactivation | 1287 |
Hereditary angioedema | 200, 254 |
Hereditary antithrombin III deficiency | 44 |
Hereditary hemochromatosis | 2128 |
Hereditary hemorrhagic telangiectasia 2 | 1047 |
Hereditary hypertriglyceridemia | 1922 |
Hereditary nonpolyposis colorectal cancer, type 2 | 2273 |
Hereditary nonpolyposis colorectal neoplasms | 2279 |
Hereditary sensory and autonomic neuropathy (type II) | 2522 |
Hereditary spastic paraplegia type 5 | 1922 |
Hereditary spastic paresis | 1922, 1984 |
Hereditary tyrosinemia type 1 | 530 |
Hermansky-Pudlak syndrome 7 | 2009 |
Herpes genitalis | 10, 296, 779 |
Herpes simplex encephalitis | 10 |
Herpes simplex infection | 10, 237, 296, 411 |
Herpes simplex labialis | 10, 255, 296, 411, 573, 779 |
Herpes simplex virus types 1 and 2 | 767 |
Herpes zoster | 10, 296, 779, 810 |
Hertwig’s epithelial root sheath/Epithelial rests of Malassez cells | 1011 |
Heterotopic ossification | 287 |
Heterozygous familial hypercholesterolemia | 299, 611, 686 |
Hiccups | 152 |
High blood pressure | 791 |
High density lipoprotein cholesterol | 992, 1143, 1363, 2012, 2249 |
High density lipoprotein deficiency type 1 | 813, 1115, 1116 |
High density lipoprotein deficiency type 2 | 813, 1115, 1116 |
High-fat diet | 1317, 1603 |
High-grade malignant glioma | 124 |
High-mobility group box protein 1 | 1143 |
High-throughput analysis of drug-drug interactions | 1760 |
High-throughput genotyping method | 1493 |
High-throughput single nucleotide polymorphism screening | 1317 |
HIP1 (Huntingtin-interacting protein 1) | 2173 |
HIP2 (Huntingtin-interacting protein 2) | 2173 |
HIP12 (Huntingtin-interacting protein 12) | 2173 |
HIP14 (Huntingtin-interacting protein 14) | 2173 |
Hippocampal neurogenesis | 1963 |
Hippocampal sclerosis | 1143 |
Hippocampal volume | 1143 |
Hirschsprung’s disease | 2379 |
Hirsutism | 259, 701 |
Histamine | 1143 |
Histamine pharmacogenetics | 2155 |
Histiocytosis | 791 |
Histone demethylase LSD1 deficiency | 1939 |
Histone methylation | 1760 |
Histone methyltransferase G9a | 1922 |
Histoplasma capsulatum | 39 |
Histoplasmosis | 310, 402, 407, 1760 |
HIV infection | 1, 2, 40, 55, 58, 224, 328, 382, 413, 451, 518, 653, 659, 660, 674, 702, 723, 801, 804, 813, 819, 875, 965, 1121, 1143, 1223, 1226, 1318, 1760, 1984, 1992, 1993, 2055, 2056, 2126, 2131, 2135, 2152, 2181, 2199, 2214, 2315, 2451 |
HIV-1 infection | 203, 207, 258, 261, 262, 291, 328, 642, 745, 2452 |
HIV-1 mother-to-child transmission | 1227 |
Hodgkin Reed-Sternberg cells | 938 |
Hodgkin’s and non-Hodgkin lymphoma | 146, 190, 195, 619, 791, 792 |
Hodgkin’s disease | 124, 196, 436, 454, 619, 703, 791 |
Hodgkin’s lymphoma | 88, 619, 792, 1761 |
Homocysteine | 1040, 1171, 1182, 1196, 1216, 2013, 2086, 2288, 2291, 2300, 2425, 2513, 2519 |
Homocystinuria | 78, 1220, 2287 |
Homology modeling | 876 |
Homophily and heterophily | 1353 |
Homotropic/Heterotropic cooperativity | 1759, 1761 |
Homozygous cystinuria | 745 |
Homozygous familial hypercholesterolemia | 294, 686 |
Homozygous sitosterolemia | 294 |
Hookworms | 453 |
Hormonal imbalance | 281 |
Hormone refractory prostate cancer | 106, 1963 |
Hormone replacement therapy | 819, 876, 1318, 1762, 2250 |
Hormone-dependent advanced prostate cancer | 101 |
Hot flushes | 273, 787, 2042 |
Human influenza | 2214 |
Human kinetic adjustment factor | 1318 |
Humectant | 698 |
Humerospinal dysostosis | 1257 |
Huntingtin (HTT) | 2172 |
Huntingtin-associated proteins | 2173 |
Huntington’s chorea | 729 |
Huntington’s disease | 710, 1061, 2096, 2173 |
Huntington’s disease-like 1 | 2350 |
Hurler and Hurler-Scheie forms | 417 |
Hyaline membrane disease | 76 |
Hydronephrosis | 1287 |
Hydroxycholesterols | 1932 |
Hyperacidity | 26, 447 |
Hyperactive children | 152 |
Hyperalphalipoproteinemia | 1244 |
Hyperammonemia | 123 |
Hyperandrogenic states in pregnancy | 1963 |
Hyperandrogenism | 2207, 2466 |
Hyperapobetalipoproteinemia | 2052, 2339 |
Hyperbilirrubinemia | 1922, 2416, 2488 |
Hypercalcemia | 108, 171, 335, 562, 806 |
Hypercholanemia | 2021 |
Hypercholesterolemia | 155, 294, 299, 323, 442, 522, 611, 618, 667, 686, 1923, 2146, 2253, 2306 |
Hypercholesterolemia, familial | 686 |
Hypercoagulability disorder | 2521 |
Hyperemia | 1049 |
Hyperglycemia | 514, 1993 |
Hyperglycemia-induced liver injury | 1603 |
Hyperhidrosis | 368 |
Hyperhomocysteinemia | 78, 1220, 1619, 2287, 2291, 2297 |
Hyperinsulinemia | 1027 |
Hyperkalemia | 111, 112, 691, 695 |
Hyperkalemic periodic paralysis | 2388 |
Hyperkinetic movement disorders | 729 |
Hyperlipidemia | 82, 597, 611, 667, 686, 819, 1120, 1144, 2253 |
Hyperlipidemia type IIB | 992 |
Hyperlipoproteinemia | 611 |
Hyperlipoproteinemia (type I) | 611 |
Hyperlipoproteinemia (type Ib) | 611 |
Hyperlipoproteinemia (type II) | 611 |
Hyperlipoproteinemia (type IIA) | 611 |
Hyperlipoproteinemia (type III) | 611 |
Hyperlipoproteinemia (type V) | 611, 1117 |
Hypermagnesemia | 111 |
Hyperosmotic laxative | 698 |
Hyperoxic lung injury | 1287 |
Hyperparathyroidism | 2268 |
Hyperparathyroidism (secondary) | 246 |
Hyperphosphatemia | 26, 110, 111 |
Hyperpigmentation | 365 |
Hyperprolactinemia | 94, 106, 635, 1549 |
Hyperprothrombinemia | 2048 |
Hypersensitivity | 2154 |
Hypersensitivity pneumonitis | 2438 |
Hypertension | 5, 21, 29, 34, 56, 70, 86, 98, 117, 125, 150, 153, 158, 175, 221, 244, 261, 268, 270, 298, 300, 331, 351, 352, 355, 361, 362, 381, 394, 401, 411, 412, 433, 441, 453, 476, 481, 482, 492, 498, 507, 515, 523, 525, 528, 542, 553, 581, 586, 612, 626, 636, 643, 650, 701, 720, 725, 742, 757, 758, 765, 782, 788, 992, 1032, 1051, 1063, 1066, 1068, 1071, 1077, 1081, 1086, 1090, 1095, 1105, 1144, 1197, 1214, 1318, 1341, 1373, 1415, 1469, 1496, 1619, 1762, 1908, 1923, 1936, 1939, 2044, 2060, 2105, 2226, 2287, 2292, 2346, 2365, 2391, 2403, 2410, 2424, 2522, 2525 |
Hypertension resistant to conventional therapy | 2299 |
Hypertension secondary to pre-eclampsia/eclampsia | 361 |
Hypertension, essential | 114, 229, 1035, 1933, 2006, 2023, 2093, 2143, 2380, 2415 |
Hypertensive crisis | 279 |
Hyperthyroidism | 471, 627, 692 |
Hypertriglyceridemia | 82, 299, 339, 522, 544, 782, 1044, 1116, 1117, 1144, 2052, 2253, 2306 |
Hypertrophic cardiomyopathy | 1036, 1939, 2281, 2346 |
Hypertrophic obstructive cardiomyopathy | 626 |
Hypertrophic subaortic stenosis | 626 |
Hyperuricemia | 21, 297, 617 |
Hypervitaminosis D | 1984 |
Hypnosedatives | 780, 1495 |
Hypoaldosteronism | 29 |
Hypocalcemia | 109, 111, 112 |
Hypocalcemic tetany | 111, 229 |
Hypochloremia | 691 |
Hypochloremic states | 35 |
Hypochlorhydria | 78 |
Hypocitraturia | 606 |
Hypodermoclysis | 360 |
Hypoestrogenism | 281 |
Hypoglycemia | 346, 1993 |
Hypogonadal osteoporosis | 727 |
Hypogonadism | 479 |
Hypogonadotropic hypogonadism | 156, 326 |
Hypokalemia | 605, 606, 701 |
Hypokalemic periodic paralysis | 222, 2388 |
Hypomagnesemia | 445, 446, 449 |
Hyponatremia | 690, 691, 754 |
Hypoparathyroidism | 109, 110, 111, 272 |
Hypophosphatemia | 272, 607, 694 |
Hypoplastic left ventricle | 24 |
Hypoprothrombinemia | 589 |
Hyposalivation | 672 |
Hypospadias | 1287 |
Hypotension | 265, 355, 587 |
Hypothalamic amenorrhea | 349 |
Hypothalamic-pituitary ACTH function | 484 |
Hypothermia | 1763 |
Hypothyroidism | 428, 431, 737, 1923, 1991 |
Hypoxemia | 556 |
Hypoxia | 1495, 1763 |
Hypoxia-induced extracellular acidosis | 877 |
Hypoxia-inducible factor 1 | 1341 |
Hypoxia-inducible factor-1alpha (HIF1A) | 877, 1011 |
Hypoxic respiratory failure | 531 |
I | |
IC50-based approaches for assessment of time-dependent inhibition of CYP3A4 | 1763 |
Ichthyosis | 1909 |
Idiopathic arthritis | 284 |
Idiopathic chronic urticaria | 254 |
Idiopathic dilated cardiomyopathy | 2445 |
Idiopathic edema | 285 |
Idiopathic hirsutism | 1963 |
Idiopathic hypereosinophilic syndrome | 2329, 2331 |
Idiopathic male infertility | 1341, 2287, 2299 |
Idiopathic Parkinson’s disease | 120, 609, 647, 665, 668, 751 |
Idiopathic pulmonary arterial hypertension | 269, 375, 762, 1047 |
Idiopathic pulmonary fibrosis | 2442 |
Idiopathic pulmonary hemosiderosis | 190 |
Idiopathic recurrent miscarriages | 2430 |
Idiopathic short stature | 697 |
Idiopathic thrombocytopenia | 665, 2226 |
Idiopathic thrombocytopenia purpura | 190, 260, 380, 651, 665 |
Idiopathic uveitis | 146, 764 |
Ifosfamide-induced hemorrhagic cystitis | 467 |
IgA deficiency | 2144 |
IgA nephropathy | 1032, 1087, 1939, 2193, 2328, 2343 |
IL1B monoclonal antibodies | 1145 |
Ileal resection | 1923 |
Illicit growth promoters in cattle | 1963 |
Immortalized non-tumorigenic human liver epithelial cells | 1766 |
Immune function | 938 |
Immunization against typhoid fever caused by Salmonella typh | 776 |
Immunization against vaccinia virus | 690 |
Immunization against varicella | 785 |
Immunization with aldehyde-modified fibronectin | 1144 |
Immunoglobulin deficiency | 379 |
Immunosuppressant | 78, 614 |
Immunotherapy | 2350 |
Immunotherapy in elderly transplant recipients | 1766 |
Impaired glucose tolerance | 2249 |
Impetigo | 309, 504, 650 |
Impotence | 479, 800 |
Impulsivity | 2259 |
In vitro fertilization | 1964 |
In vitro interaction cocktail assays | 1771 |
In vitro systems for assessment of CYP3A4 induction | 1771 |
Inactivating mutations in the GNAS gene | 2090 |
Inactive chloasma | 365 |
Inclusion body myositis | 1144 |
Increased frequency of APOE-4 in AD and protective effect of APOE-2 | 1127 |
Indigestion | 144 |
Individual variation | 1603 |
Inducers | 938 |
Inducers and inhibitors | 1341 |
Induction of labor at term | 558 |
Induction of ovulation | 462 |
Industrial carcinogens | 2109 |
Infant birth size | 1095 |
Infant botulism | 92 |
Infant colic | 368 |
Infantile hypertrophic cardiomyopathy | 2280 |
Infantile parkinsonism-dystonia syndrome | 2396 |
Infantile spasms | 186, 755, 790 |
Infected dermatoses | 532 |
Infected or noninfected wounds | 409 |
Infection respiratory tract | 700 |
Infections | 147, 248, 608, 1144 |
Infections by gram-positive bacilli | 65 |
Infections of the skin | 63 |
Infections of the upper and lower respiratory tract | 138 |
Infectious diarrhea | 162 |
Infectious mononucleosis | 2130 |
Infective endocarditis | 38, 39, 169, 201 |
Infertility | 337, 2038, 2075 |
Infertility in Etv5-/- female mice | 1963 |
Inflammasome | 1144 |
Inflammation | 16, 53, 76, 94, 119, 170, 171, 192, 214, 223, 226, 227, 255, 291, 307, 322, 363, 365, 409, 413, 416, 440, 441, 448, 520, 524, 570, 657, 812, 992, 2167 |
Inflammatory bowel disease | 437, 631, 878, 1767, 1909, 1923, 2176, 2193, 2197, 2200, 2227, 2311, 2343, 2370, 2403, 2430, 2456, 2477 |
Inflammatory bowel disease 5 | 2408 |
Inflammatory conditions | 316, 359, 441, 448, 764, 2359, 2360, 2362 |
Inflammatory dermatosis | 78, 314, 613, 764 |
Inflammatory disease | 5, 63, 137, 169, 540, 371, 709, 938 |
Inflammatory myopathy | 2058 |
Inflammatory phase of xerosis | 78 |
Influence of APOE-CYP2D6 interactions on Alzheimer’s disease therapeutics | 1128 |
Influence of CYP2D6 genotypes on liver transaminase activity | 1442 |
Influenza | 255, 385, 548, 656, 803, 2144 |
Influenza vaccination | 1144 |
Insect bites and stings | 73, 287 |
Insomnia | 35, 96, 144, 249, 273, 280, 284, 320, 359, 437, 439, 530, 634, 643, 677, 720, 765, 780, 802, 808, 809 |
Insufficient blood flow | 791 |
Insulin resistance | 1058, 1081, 2054, 2384, 2427 |
Insulin resistance, susceptibility to | 1081 |
Insulin secretion | 878 |
Insulin sensitivity | 2093, 2247, 2344, 2346 |
Insulin-dependent diabetes mellitus | 610, 1274, 2207 |
Insulin-like growth factor-1 | 1145, 1768, 1963 |
Insulin-like growth factor-1 deficiency | 454, 2188 |
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors | 1768 |
Insulinoma and pancreatic cancer | 2297 |
Intensive care | 624 |
Interactions of anti-cancer drugs | 879 |
Interleukin 1 receptor antagonist deficiency | 2197 |
Intermediate metabolizers | 1506 |
Intermittent claudication | 159, 342, 579 |
Interruption of aortic arch | 24 |
Interstitial cystitis | 231, 578 |
Intestinal amebiasis | 248, 391, 566, 743 |
Intestinal CYP3A and regulation of detoxifying systems in the liver | 1768 |
Intestinal CYPs | 1619 |
Intestinal expression | 938 |
Intestinal metabolism | 1768 |
Intestinal metabolizing enzymes | 1363, 1984 |
Intestinal metaplasia | 2307 |
Intestinal tract | 820 |
Intestinal transporters | 879 |
Intimal hyperplasia | 2364 |
Intra-abdominal and urinary tract infections | 137 |
Intra-abdominal infections | 132, 133, 162, 242, 275, 377, 465, 483, 741 |
Intracerebral hemorrhage | 1145 |
Intracranial hemorrhage in brain arteriovenous malformations | 1047, 2207 |
Intracranial hypertension | 734 |
Intracranial pressure | 450, 734 |
Intracranial volume and white matter lesions | 1145 |
Intractable chronic pain | 803 |
Intrahepatic cholestasis | 1923 |
Intrahepatic cholestasis of pregnancy | 929 |
Intraocular hypertension | 125, 418, 423, 612, 742, 761 |
Intraocular pressure | 46, 423, 450 |
Intratumoral aromatase deficiency | 1963 |
Intrauterine growth | 2088 |
Intrauterine growth retardation associated with precocious puberty and sertoli cell hyperplasia (Russell-Silver syndrome-like phenotype) | 1963 |
Intronic polymorphisms | 1498 |
Invasive aspergillosis | 795, 2452 |
Invasive cervical cancer | 2136 |
Invasive fungal infections | 795, 1416 |
Invasive pneumococcal disease | 2197 |
Ionizing radiation | 1923 |
IQ | 1145 |
Iridectomy | 9 |
Iridocyclitis | 677, 773 |
Iron deficiency anemia, susceptibility to | 396 |
Iron deprivation | 879 |
Iron-deficiency anemia | 302, 303, 396, 602 |
Irrigating solution | 66 |
Irritable bowel syndrome | 22, 70, 224, 368, 443, 592, 624, 718, 768, 1066, 2093, 2456, 2475 |
Irritations | 805 |
Ischemia | 2112 |
Ischemia-reperfusion injury | 879, 1374, 1469 |
Ischemic and hemorrhagic stroke | 1051 |
Ischemic cerebrovascular disease | 1119, 1269, 1477 |
Ischemic heart disease | 1269, 2292, 2299, 2424 |
Ischemic stroke | 611, 1059, 1079, 2056, 2060, 2203, 2225, 2287, 2306, 2353, 2370, 2445 |
Islet cell carcinoma | 196 |
Isolated growth hormone deficiency | 2086 |
Isolated growth hormone deficiency (type IA) | 2086 |
Isolated growth hormone deficiency (type IB) | 2086 |
Isolated growth hormone deficiency (type II) | 2086 |
Ispinesib/docetaxel combination-induced myelosuppression | 1773 |
Itching eyes | 75, 771 |
Ivermectin-sensitive Border Collie | 880 |
J | |
Japanese encephalitis | 405 |
Jervell and Lange-Nielsen syndrome 1 | 2235 |
Jervell and Lange-Nielsen syndrome 2 | 2228 |
Joint osteoarthritis | 2197 |
Juvenile idiopathic arthritis | 3, 11, 288, 2200, 2215 |
Juvenile onset cholestasis | 1923 |
Juvenile rheumatoid arthritis | 73, 139, 223, 288, 371, 459, 512, 550, 752 |
K | |
KATP channels | 983 |
Kaposi’s sarcoma | 198, 791, 2207 |
Kawasaki disease | 380, 1227, 2134, 2215, 2476 |
Kearns-Sayre syndrome | 2285 |
Keloid | 764 |
Keratinocytes | 1288 |
Keratitis | 514, 773 |
Keratoconjunctivitis sicca-associated ocular inflammation | 192 |
Keratoplasty | 9 |
Kidney angiomyolipoma | 2182 |
Kidney diseases | 1091, 2048 |
Kidney failure | 1087 |
Kidney proximal tubular cells | 1776 |
Kidney transplant rejection | 1274 |
Kidney transplantation | 61, 714, 780, 881 |
Klebsiella | 39, 128 |
Klinefelter’s syndrome | 1185, 1964 |
Kohonen maps | 1776 |
Korsakoff’s syndrome | 733 |
Kowarski syndrome | 2086 |
Kuru | 2350 |
L | |
Lacrimation | 771 |
Lactase deficiency | 2243 |
Lactation | 1924 |
Lactose intolerance | 412 |
Lacunar infarcts | 1105 |
Lambert-Eaton myasthenic syndrome | 28 |
Lamellar ichthyosis type 3 | 1909 |
Langerhans cell differentiation | 1013 |
LAPTM4B | 882 |
Large-joint osteoarthritis | 1964 |
Laron syndrome | 2088 |
Larsen’s syndrome | 1257 |
Laryngeal carcinoma | 1013 |
Laryngeal squamous cell carcinoma | 882, 1288, 1778 |
Laryngospasm | 2388 |
Larynx | 1904 |
Larynx cancer | 1221 |
Late-onset Alzheimer’s disease | 812, 1220, 2300 |
LDL-cholesterol | 611, 2245, 2338 |
Lead encephalopathy | 257 |
Lead poisoning | 231, 257, 705, 1100 |
Lead poisoning, susceptibility to | 257 |
Leber’s hereditary optic neuropathy | 2280, 2281, 2282, 2283 |
Lecithin cholesterol acyltransferase deficiency | 992 |
Left ventricular dysfunction | 261 |
Left ventricular dysfunction postmyocardial infarction | 117, 125, 758, 782 |
Left ventricular failure | 502 |
Left ventricular hypertrophy | 441, 1036, 1939, 2306 |
Left ventricular hypervoltage | 1940 |
Left ventricular mass | 2093 |
Left ventricular systolic dysfunction | 2339 |
Legionella pneumonia | 654 |
Leigh’s syndrome | 2280, 2283 |
Lennox-Gastaut syndrome | 297, 414, 669, 755 |
Lentigo | 365 |
Lepidoptera | 882 |
Leprosy | 201, 2183, 2216, 2219, 2255, 2326 |
Leptin receptor | 1146 |
Leptospirosis | 1146, 2130 |
Letrozole and Norethisterone acetate vs Letrozole and Triptorelin in endometriosis | 1965 |
Letrozole, Misoprostol and Mifepristone in therapeutic abortion | 1965 |
Letterer-Siwe disease | 791 |
Leucine-induced hypoglycemia | 983 |
Leukapheresis | 577 |
Leukemia | 473, 791, 882, 964, 969, 978, 1363, 1778, 2307, 2240 |
Leukemia, acute lymphocytic | 190, 195 |
Leukopenia | 2314 |
Leukotriene B4 receptor-1 | 1146 |
Levodopa-induced dyskinesia | 1146 |
Lewis lung carcinoma | 1013 |
Lewy body dementia | 713, 2350, 2420 |
Lichen planus plaques | 764 |
Lichen simplex chronicus plaques | 764 |
Liddle’s syndrome | 2391 |
Life-threatening ventricular arrhythmias | 623, 748 |
Li-Fraumeni syndrome | 2471 |
Ligula intestinalis infection | 1965 |
Lipid A | 2184, 2220, 2453 |
Lipid abnormalities | 2207 |
Lipid peroxides | 2106, 2111, 2121 |
Lipids | 820, 883, 1242 |
Lipid rafts | 820, 939 |
Lipodystrophy | 1083, 2247, 2334, 2375 |
Lipodystrophy induced by antiretroviral therapy in HIV patients | 1146 |
Lipomatosis | 675 |
Lipophilicity | 1502 |
Lipoprotein glomerulopathy | 1146 |
Lipoprotein lipase | 1146 |
Lipoprotein lipase deficiency | 2253 |
Lipoxygenase | 993 |
Liquid chromatography-tandem mass spectrometry analysis | 1780 |
Listeria infections | 39 |
Lithocholic acid-induced liver injury | 1984 |
Liver cancer | 883, 1604, 1781, 1940, 2110, 2295, 2297, 2518 |
Liver cirrhosis | 1056, 2499 |
Liver disease | 388, 1013, 1105, 1502, 1781 |
Liver drug metabolism transcriptome | 1781 |
Liver fatty acid binding protein | 1924 |
Liver fibrosis | 883 |
Liver receptor homolog-1 | 1924, 1965 |
Liver regeneration | 1924 |
Liver transplantation | 1416, 1503, 1781 |
Liver X receptor | 1013, 1288 |
Liver X receptor agonists | 820, 1781 |
Liver X receptor alpha (LXRα) | 993 |
Liver X receptor alpha/ NR1H3 | 1147 |
Liver X receptor-activating ligands (DMHCA, TO901317) | 1146 |
Local anesthesia | 99, 464, 616, 666, 730 |
Loeys-Dietz syndrome | 2448 |
Long QT syndrome | 1072, 2154, 2229, 2230, 2231, 2235, 2390 |
Long QT syndrome-1 | 1072 |
Long QT syndrome 1/2 | 2231, 2235 |
Long QT syndrome 2 | 2231 |
Long QT syndrome 2/3 | 2231 |
Long QT syndrome 2/5 | 2231 |
Long QT syndrome 2/9 | 2231 |
Longevity | 1014, 1049, 1147, 1244, 1374, 1965 |
Loss of transport function of SLC15A2 | 2404 |
Low bone mineral content | 2249 |
Low-density lipoproteins (LDL) | 820 |
Low-density lipoprotein receptor-related protein 1b (LRP1b) | 993, 1147 |
Lower respiratory tract disease | 561 |
Lower respiratory tract infections | 63, 128, 137, 162, |
Lower urinary tract | 1063 |
Low-grade non-Hodgkin lymphoma | 757 |
Lung adenocarcinoma | 2018, 2140, 2236, 2333 |
Lung cancer | 190, 237, 274, 338, 436, 473, 619, 792, 884, 939, 969, 1014, 1056, 1254, 1288, 1320, 1342, 1353, 1504, 1604, 1784, 1904, 1965, 2018, 2021, 2025, 2033, 2110, 2116, 2120, 2130, 2134, 2144, 2240, 2242, 2295, 2297, 2308, 2319, 2337, 2362, 2370, 2379, 2404, 2405, 2442, 2450, 2471, 2515, 2526, 2528 |
Lung cancer risk | 1254, 2055, 2337 |
Lung cells | 1784 |
Lung diseases | 2193 |
Lung transcriptome | 1288 |
Lupus | 2060 |
Lupus erythematosus | 366, 1269, 2060, 2179, 2227 |
Lupus nephritis | 190, 2183 |
Luteinizing hormone | 1965 |
Luteinizing hormone-releasing hormone agonists | 1965 |
Lyme disease | 138 |
Lymphatic metastasis in gastric carcinoma | 2331 |
Lymphedema | 285, 1785 |
Lymphoblastic leukemia | 2227 |
Lymphocytes | 1619, 1785 |
Lymphocytic leukemia | 247, 2471 |
Lymphoid leucemia | 1237 |
Lymphoma | 103, 473, 495, 736, 885, 1240 |
Lymphoma, non-Hodgkin | 619, 757, 791 |
Lymphoplasmacytic enteritis | 885 |
Lymphoproliferative disorders | 2021 |
Lynch syndrome | 1288 |
LXR-Alpha | 954 |
M | |
Macrocytic anemia | 325 |
Macroglobulinemia | 190 |
Macrophage stimulatory lipopeptide 2 | 2372 |
Macrophage lipid metabolism | 993 |
Macrophages | 820, 885 |
Macular degeneration | 790, 2158, 2253 |
MAD2 | 885 |
Madurella mycetomatis-induced mycetoma | 1965 |
Maintenance of normal microflora in the gastrointestinal tract | 671 |
Major depressive disorder | 14, 49, 100, 213, 252, 317, 567, 678, 681, 759, 787, 886, 1258, 1483, 2009, 2101, 2159, 2163, 2168, 2170, 2193, 2259, 2316, 2319, 2396, 2398, 2439, 2456, 2475, 2476 |
Major PRNP variants associated with prion disease | 2350 |
Malabsorption syndrome | 562 |
Malaria | 36, 51, 149, 248, 255, 366, 458, 622, 633, 708, 886, 1320, 1786, 1990, 2056, 2078, 2134, 2153, 2176, 2219 |
Male hypogonadism | 728 |
Male infertility | 1096, 1186, 2335, 2526, 2528 |
Malignant ascites | 127 |
Malignant gliomas | 2329 |
Malignant hypertension | 221 |
Malignant hyperthermia | 200, 2382 |
Malignant lymphomas | 247 |
Malignant melanoma | 196, 387 |
Malignant mesothelioma | 993, 1966 |
Malignant murine skin tumors | 1966 |
Malignant osteopetrosis | 390 |
Malignant pleural effusion | 715 |
Malignant pleural mesothelioma | 573 |
Mammary tissue | 820 |
Mandibular height | 2088 |
Manganese deficiency | 449 |
Manganese intoxication | 1504 |
Mania | 152, 434 |
Mantle cell lymphoma | 89, 1233 |
Maroteaux-Lamy syndrome | 336 |
Masculinization | 1966 |
Mast cell leukemia | 2238 |
Mastitis | 309 |
Mastocytosis | 2238 |
Maternal behavior | 1966 |
Maternal depression effects on fetal neurodevelopment | 2398 |
Maternal fine particulate matter exposure | 1504 |
Maternal protein restriction-related epigenetic changes in offspring cholesterol | 1925 |
Maternal tobacco use and risk of adverse pregnancy outcomes | 1353 |
Maternal undernutrition | 1940 |
Maternally transmitted diabetes mellitus-deafness syndrome | 2284 |
Maturity-onset diabetes of the young | 1201 |
Maturity-onset diabetes of the young type 1 (MODY1) | 2149 |
McCune-Albright syndrome | 1966, 2090 |
MDMA and designer drugs of the amphetamine type | 1478, 1555 |
MDMA-induced neurotoxicity | 1479 |
MDR1 RNAi | 886 |
Measles (rubeola) | 379, 452, 453 |
Mechanical ventilation | 663 |
Mediterranean diet | 1147 |
Medullary thyroid carcinoma | 196, 2379 |
Medulloblastoma | 124 |
Megaloblastic anemia | 325 |
Melanoma | 17, 198, 367, 436, 619, 886, 939, 1231, 1240, 1984, 2027, 2031, 2211, 2238, 2267, 2331, 2515 |
MELAS syndrome | 2282, 2283, 2285 |
Melatonin and Silymarin in maneb- and paraquat-induced Parkinson’s disease phenotype | 1604 |
Membranoproliferative glomerulonephritis | 1245 |
Memory | 1147, 2163 |
Memory deficits | 342, 791 |
Memory disorder | 596 |
Menarche | 1966 |
Meniere’s disease | 77, 161 |
Meningeal carcinomatosis | 1966 |
Meningeal leukemia | 195 |
Meningitis | 132, 137, 310 |
Meningococcal disease | 39, 461, 2056 |
Meningoencephalitic stage of Trypanosoma brucei gambiense infection | 259 |
Menkes’ disease | 1193 |
Menopausal neurosis | 702 |
Menopause | 255, 281, 283, 1320, 1788, 2038 |
Menstrual cycle | 1788, 2075 |
Mental development | 1342 |
Mental disorders | 1505, 1997, 2007 |
Mental retardation | 1991 |
Mental retardation X-linked type 63 (MRX63) | 1045 |
MEOS (Microsomal Ethanol-Oxidizing System) | 1788 |
Merkel cell carcinomas | 2329 |
MERRF syndrome | 2284, 2285, 2335 |
Mesothelioma | 887 |
Meta-analysis of association studies investigating genes for PD | 1531 |
Metabolic acidosis | 690, 691, 693, 772 |
Metabolic alkalosis | 35 |
Metabolic bone diseases | 2038 |
Metabolic syndrome | 994, 1033, 1043, 1059, 1078, 1081, 1087, 1091, 1117, 1120, 1148, 1269, 1789, 1925, 1940, 1966, 2052, 2165, 2177, 2198, 2211, 2245, 2255, 2292, 2339, 2452 |
Metabolic traits | 1148 |
Metabolism of neurosteroids | 1479 |
Metabolizing capacity | 1505 |
Metastatic brain tumors | 124 |
Metastatic breast cancer | 115, 274, 338, 416, 479, 511, 715, 728, 756 |
Metastatic colorectal cancer | 81, 115, 143, 563, 2058 |
Metastatic islet cell carcinoma of the pancreas | 704 |
Metastatic ovarian carcinoma | 247, 367 |
Metastatic prostate cancer | 83 |
Metastatic tumors | 454 |
Methanol or Ethylene glycol poisoning | 326 |
Methotrexate toxicity | 421, 1049, 1191 |
Methylation-related Tamoxifen resistance | 1508 |
Methylcobalamin deficiency (cblG type) | 2291 |
Methylenetetrahydrofolate reductase | 1925 |
MGMT promoter methylation | 2271 |
Microangiopathic ischemic stroke | 1269 |
Microchimerism | 2456 |
Microglia | 1148 |
Micropenis | 2426 |
MicroRNAs | 821, 994, 1015, 1793, 1925, 1967 |
Microsporum infection | 725 |
Middle ear infections | 556 |
Migraine | 22, 90, 144, 255, 259, 313, 332, 480, 507, 513, 599, 662, 711, 742, 755, 780, 807, 1263, 1511, 1795, 1989, 2014, 2038, 2160, 2161, 2456, 2476 |
Migraine with aura | 259, 313, 332, 662, 807, 1989, 2287 |
Migraine without aura | 662, 807, 1989 |
Mild cognitive impairment | 1148 |
Mild-to-moderate metabolic acidosis | 690, 691, 693 |
Mild-to-moderate pain | 180, 226, 371, 408, 448, 512, 457, 625, 673 |
Milk cholesterol secretion | 994 |
Milk fatty acids and traits | 1015 |
Mineralocorticoid receptor activation | 1940 |
Minor burns | 73, 610 |
Miosis | 321 |
miR-378 | 1604 |
Mismatch repair cancer syndrome | 2273, 2279 |
Mitochondrial CYP2E1 | 1605 |
Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome (MELAS) | 2282, 2283, 2285 |
Mitochondrial neurogastrointestinal encephalopathy syndrome | 2335 |
Mitochondrial permeability transition pore | 888 |
Mitogen-activated protein kinases (MAPKs) | 1364, 1796 |
Mixed dyslipidemia | 299, 675 |
Mixed hyperlipidemia | 82, 294, 611, 667 |
Moisturizer for dry, rough skin | 777 |
Molecular interaction fields | 889 |
Monoamine metabolite concentrations | 2167 |
Monocyte locomotion inhibitory factor | 2185, 2195, 2201, 2209, 2217 |
Monocytic leukocytes | 1619 |
Mood disorders | 1050, 2001, 2399 |
Moraxella catarrhalis | 63 |
Morbid obesity | 2249, 2344 |
Morbid obesity with hypogonadism | 2247 |
Morganella morganii | 119 |
Morphea | 607 |
Motion sickness | 161, 189, 232, 455, 622, 677 |
Mountain sickness | 1033, 1087, 1119 |
Moyamoya disease | 2278 |
Muckle-Wells syndrome | 113, 656 |
Mucopolysaccharidosis I | 417 |
Mucopolysaccharidosis VI | 336 |
Mucosal-associated invariant T (MAIT) cells | 889 |
Mucositis | 73, 672 |
Muir-Torre syndrome | 2274, 2279 |
Multidrug resistance gene HA117 | 889 |
Multinodular goiter | 737 |
Multiple endocrine adenomas | 296 |
Multiple endocrine neoplasia, type I | 2268 |
Multiple endocrine neoplasia, type II | 2379 |
Multiple myeloma | 89, 124, 190, 460, 562, 599, 619, 732, 806, 890, 1342, 1417, 1799, 1990, 2211 |
Multiple pterygium syndrome | 1252 |
Multiple sclerosis | 190, 198, 200, 306, 389, 495, 514, 613, 889, 1149, 1227, 1274, 1984, 2131, 2139, 2144, 2183, 2193, 2198, 2200, 2255, 2267, 2270, 2344, 2361, 2445, 2465 |
Multiple system atrophy | 2420 |
Multixenobiotic transporters | 890 |
Mumps | 452, 453 |
Muscle paralysis | 609 |
Muscle spasm | 123, 154, 189, 472, 677 |
Muscle spasticity | 747 |
Musculoskeletal pain | 154, 468, 772, 2163 |
Mushroom poisoning | 632 |
Myalgia in statin-treated patients | 2168 |
Myasthenia gravis | 27, 186, 190, 257, 360, 519, 609, 632, 890, 1038, 1252 |
Myasthenia gravis with thymus hyperplasia | 609 |
Myasthenic syndrome | 2388 |
Mycetoma (Madurella mycetomatis) | 1342 |
Mycobacterial diseases | 285 |
Mycobacterial infection | 406, 653, 704 |
Mycobacterium tubercolosis infection | 2401 |
Mycoplasma pneumoniae | 719 |
Mycosis fungoides | 190, 454, 791 |
Mydriasis | 59, 190, 773, 800 |
Myeloblastic and lymphoid cell lines | 1799 |
Myelodysplastic syndrome | 60, 205, 419, 795, 1046, 1271, 1799, 2120, 2128, 2285 |
Myeloid reconstitution | 675 |
Myeloid/lymphoid or mixed lineage leukemia | 2101 |
Myelopoiesis | 1149 |
Myocardial infarction (MI) | 53, 176, 327, 433, 502, 611, 626, 643, 703, 742, 1015, 1033, 1056, 1059, 1072, 1091, 1149, 1189, 1227, 1375, 1392, 1417, 1515, 1619, 1799, 1909, 1925, 2038, 2050, 2051, 2060, 2146, 2226, 2250, 2255, 2256, 2282, 2306, 2365, 2370, 2440, 2450, 2452 |
Myocardial injury | 2226 |
Myocardial ischemia | 565, 611, 626, 643, 703, 1087 |
Myoclonic epilepsy associated with ragged-red fibers | 2284, 2285, 2335 |
Myoclonic seizures | 174, 530 |
Myoclonus | 1535 |
Myofascial pain syndrome | 287 |
Myoma | 1967 |
Myoneural gastrointestinal encephalopathy syndrome | 2284 |
Myophosphorylase deficiency | 1033 |
Myosin regulatory light chain | 890 |
Myositis | 234 |
Myositis ossificans | 287 |
Myxedema coma/precoma | 431 |
N | |
N-Acetyltransferases | 1322 |
NAD | 1216, 2473 |
NADP | 1295, 1346, 1368, 1400, 1423, 1613, 2352 |
NADPH-CYP450 oxidoreductase | 1322, 1799 |
N-Containing drugs and xenobiotics oxygenated by FMO1 | 2065 |
N-Dealkylation | 1516 |
Nano-biotechnology culture system | 1800 |
Nanoparticles | 891, 1800 |
Narcolepsy | 38, 49, 218, 478, 497, 693 |
Narrow complex tachycardia | 618 |
Narrow-angle glaucoma | 471 |
Nasal and nasopharyngeal mucosal congestion | 799 |
Nasal congestion | 255, 266, 512, 630, 731, 799 |
Nasal delivery | 891 |
Nasal mucosa | 1904 |
Nasal polyps | 69, 97, 499 |
Nasopharyngeal carcinoma | 940, 1015, 1605, 1620, 1801, 1904, 2131, 2153, 2275, 2471 |
Nasopharyngeal mucosal congestion | 799 |
Natural killer-cell neoplasms | 891 |
Nausea/vomiting | 46, 144, 152, 161, 189, 230, 239, 249, 250, 329, 350, 546, 677, 1535, 2168 |
Necrobiosis lipoidica diabeticorum | 764 |
NEDD9 | 1149 |
Neonatal alloimmune thrombocytopenia | 2225 |
Neonatal diabetes mellitus | 2233 |
Neonatal gastroesophageal reflux disease | 1417 |
Neonatal severe hyperparathyroidism | 1212 |
Neoplasm | 234, 613, 764, 1988, 1995, 2179, 2271, 2471, 2526 |
Neovascular (wet) age-related macular degeneration | 644 |
Nephritic syndrome | 362, 701 |
Nephropathic cystinosis | 194 |
Nephropathy | 21 |
Nephrotic syndrome | 153, 190, 333, 381, 476, 764, 812, 892 |
Nephrotoxicity | 1375, 2408 |
Nephrotoxicity associated with cisplatin therapy | 695 |
Neprilysin | 1149 |
Nerve growth factor-mediated neurite outgrowth | 1150 |
Nervous tension | 359 |
Neural stem cell | 1150 |
Neural tube defects | 325, 2288, 2291 |
Neuralgia | 234, 334, 359, 702, 772 |
Neuritic plaques | 1150 |
Neuroblastoma | 164, 190, 196, 198, 247, 290, 400, 460, 755,791, 907, 940, 2190, 2207 |
Neurocysticercosis | 14, 2453 |
Neurodegenerative disorders | 141, 994, 2103, 2295 |
Neurodermatitis | 78 |
Neurofibrillary tangles | 2101 |
Neurogenic bladder | 80, 368, 554 |
Neurogenic bowel disturbances | 70 |
Neuroinflammation | 1968 |
Neuroleptic malignant syndrome | 1457, 1488, 1517, 1549 |
Neuroleptic-related weight gain in schizophrenia | 1064 |
Neurological toxicities | 632 |
Neuromuscular blockade | 368 |
Neuromyelitis optica | 1925 |
Neuronal excitability and survival | 2071 |
Neuropathic pain | 755, 787, 1803 |
Neuropathy, ataxia, and retinitis pigmentosa | 2280 |
Neuropsychiatric disorder and early-onset cataract | 2285 |
Neurotic disorders | 37 |
Neurotransmitters | 1803 |
Neutralization of heparin during surgery or dialysis | 627 |
Neutropenia | 305 |
Neutropenic allogeneic hematopoietic stem cell recipients | 795 |
Neutropenic fever | 795 |
Neutrophil growth factors | 1392 |
NF-kappaB | 894, 1803, 1808 |
N-glycosylation of ABC transporters | 892 |
NHERF-1 (Na+/H+ exchanger regulatory factor 1) | 956 |
N-in-1 dosing pharmacokinetics | 1804 |
Nicotine addiction | 1250, 1356, 1998, 2002, 2003 |
Nicotine dependence | 2007, 2399 |
Nicotine dependence, susceptibility to | 1997 |
Nicotine replacement therapy | 2323 |
Niemann-Pick C1 protein | 1925 |
Niemann-Pick disease | 2304 |
Niemann-Pick disease, type C | 821, 1150 |
Niemann-Pick disease, type C1 | 2304 |
Niemann-Pick disease, type D | 2304 |
Nighttime sleep aid | 232 |
Nitrous oxide sensitivity in MTHFR deficiency | 2288 |
NK-Cell leukemia | 892 |
Nocardiosis | 708, 709 |
Nocturia | 307 |
Nocturnal asthma | 328 |
Nocturnal enuresis | 378 |
Nocturnal frontal lobe epilepsy (type 1) | 1253 |
Nodular acne | 400 |
Noise-induced hearing loss | 2229 |
Non-alcoholic fatty liver disease | 994, 1323, 1605, 1807, 2332, 2489 |
Non-alcoholic steatohepatitis | 1605 |
Non-articular rheumatism | 5 |
Non-atopic asthma | 2203 |
Non-coding vault RNAs | 1807 |
Non-erosive reflux disease | 279 |
Non-familial idiopathic cardiomyopathy | 2145, 2422 |
Non-familial structural atrial fibrillation | 1940 |
Non-familiar atrial fibrillation | 2231 |
Non-fatal myocardial infarction and stroke | 2225 |
Non-gonococcal urethritis | 276 |
Non-growth hormone-deficient short stature | 697 |
Non-Hodgkin lymphoma | 88, 124, 370, 436, 454, 599, 619, 757, 791, 792, 893, 1096, 1605, 2056, 2058, 2255, 2279, 2288 |
Non-hypertrophic AK on face or scalp | 379 |
Non-insulin-dependent diabetes mellitus | 344, 610, 649, 667, 689, 750, 751, 984, 2120, 2150, 2207, 2233, 2250 |
Non-lymphocytic leukemias | 495 |
Non-metastatic gestational trophoblastic disease | 231 |
Non-myeloid malignancies | 269 |
Non-obstructive urinary retention | 80 |
Non-productive cough | 73 |
Non-Q-wave myocardial infarction | 199, 271 |
Non-small cell lung cancer | 338, 559, 573, 603, 723, 793, 893, 940, 964, 1016, 1240, 1342, 1375, 1807, 1968, 2018, 2029, 2031, 2193, 2224, 2528 |
Non-spherocytic hemolytic anemia | 2078 |
Non-squamous non-small cell lung cancer | 81 |
Non-steroidal anti-inflammatory drug-associated gastrointestinal bleeding | 1393 |
Non-ST-segment elevation | 176, 262, 263, 271, 531, 610, 637 |
Non-syndromic sensorineural deafness | 2284 |
Non-toxic goiter | 431 |
Non-ulcer dyspepsia | 163 |
Non-viral hepatitis-related hepatocellular carcinoma | 1968 |
Noonan’s syndrome | 697, 1204, 2240, 2430 |
Normal tension glaucoma | 2014 |
Normal-pressure hydrocephalus | 1150 |
NOS1 promoter repeat | 1150 |
Nosocomial pneumonia | 162, 426, 430 |
Novel substrates | 1808 |
Nox1 NADPH oxidase | 1150 |
Nrf2-dependent gene expression | 1151 |
NSAID-associated gastric ulcer | 415 |
NT5E deficiency (arterial calcification due to deficiency of CD73) | 978 |
Nuclear factor (erythroid-derived 2)-like 2 | 1016 |
Nuclear factor-erythroid 2 related factor 2 | 1354 |
Nuclear receptors | 1808 |
Nuclear receptors in oncology | 1808 |
Nuclear transcription factors | 1809 |
Nucleotides | 2227, 2324 |
Nutrigenetics (gene-diet interaction) | 1151 |
Nutritional disturbances | 699 |
Nutritional factors | 1522 |
Nutritional supplement | 188 |
O | |
Obesity | 225, 470, 547, 583, 586, 683, 821, 894, 994, 1059, 1059, 1067, 1072, 1078, 1081, 1088, 1151, 1203, 1269, 1323, 1926, 1968, 2001, 2079, 2093, 2107, 2170, 2207, 2243, 2249, 2253, 2292, 2304, 2306, 2337, 2346, 2427, 2483 |
Obesity (severe) due to leptin deficiency | 2247 |
Obesity and body mass index | 2342, 2344 |
Obesity, hyperphagia, and developmental delay | 2320 |
Obesity, susceptibility to | 1067, 1072, 1078, 1081, 1269, 2001 |
Obesity-related fatty liver | 1926 |
Obsessive-compulsive disorder | 173, 317, 324, 567, 681, 787, 1522, 2096, 2160, 2163, 2167, 2399 |
Obsessive-compulsive disorder, susceptibility to | 2096 |
Obstructive airway disease | 422, 673 |
Obstructive sleep apnea syndrome | 49, 2014 |
Occipital horn syndrome | 1193 |
Occluded arteriovenous cannulas | 703 |
Occult subfoveal choroidal neovascularization | 790 |
Ocular aspergillosis | 39 |
Ocular histoplasmosis | 790 |
Ocular hypertension | 79, 84, 92, 93, 242, 418, 742, 761 |
Ocular infections | 162, 768 |
Ocular inflammation | 94, 192, 657, 764 |
Ocular itching | 409, 543 |
O-Glycosylation | 1151 |
Oil sediment genotoxicity | 1940 |
Oleoyl-Coenzyme A | 2106 |
Oligoarticular juvenile idiopathic arthritis | 2140 |
Oligodendroglioma | 1002 |
Oliguria | 450 |
Omani type spondylo-epiphyseal dysplasia | 1257 |
Omeprazole-Amoxicillin dual therapy for Helicobacter pylori eradication | 1417 |
Onchocerciasis | 403, 712, 2140 |
One-and two-sided undescended testicles | 349 |
Ontogenesis of CYP1A proteins | 1497 |
Ontogeny | 1812 |
Onychomycoses | 158, 402, 725, 1567, 1812 |
Oocytes | 894 |
Open-angle glaucoma | 84, 92, 93, 242, 256, 418, 423, 471, 480, 761, 1073, 1077, 2337 |
Ophthalmic diseases | 613 |
Ophthalmic epinephrine sensitivity reaction | 457 |
Ophthalmic infections | 341, 748 |
Opiate dependence | 99, 2323 |
Opioid-related disorders | 510 |
Opisthorchiasis | 14, 612 |
Opisthorchis viverrini-associated cholangiocarcinoma | 1354, 1606 |
Oral and laryngeal cancer | 1054 |
Oral cancer | 1289, 1606, 2190 |
Oral drug overdose | 393 |
Oral lesions | 449, 764 |
Oral mucositis | 253, 560 |
Oral squamous cell carcinoma | 1016, 1342, 1606, 2289 |
Oral ulcer | 449 |
Organ transplantation | 895 |
Organic anion-transporting polypeptides | 1926 |
Organic solute transporter α deficiency | 1926 |
Organophosphate poisoning, sensitivity to | 609 |
Orofacial infections | 223, 700 |
Orolaryngeal carcinoma | 2505 |
Oronasopharyngeal itching | 771 |
Oropharyngeal candidiasis | 177, 310, 603 |
Oropharyngeal mucositis | 75 |
Orphan nuclear receptors | 895 |
Orthostatic hypotension | 265,488 |
Orthostatic intolerance | 2395 |
Osteitis deformans | 742 |
Osteoarthritis | 53, 77, 116, 139, 155, 223, 226, 288, 291, 300, 307, 321, 383, 408, 440, 448, 459, 506, 512, 527, 550, 597, 704, 709, 724, 738, 752, 1186, 1991, 2198 |
Osteoarthrosis | 5 |
Osteogenesis imperfecta | 1261 |
Osteogenic sarcoma | 247, 2375 |
Osteolytic bone lesions | 562 |
Osteomalacia | 110, 111, 1814 |
Osteomyelitis | 76, 223, 309, 508, 549 |
Osteonecrosis | 1375, 1814 |
Osteopenia | 2207 |
Osteoporosis | 18, 67, 108, 110, 111, 112, 113, 209, 281, 287, 370, 417, 550, 562, 641, 657, 727, 806, 1261, 1969, 2064, 2193, 2198, 2207, 2515 |
Osteoporosis, postmenopausal | 209, 417, 641, 657, 727, 806 |
Osteoporotic fracture risk | 2337 |
Osteosarcoma | 473, 895, 1017, 1814, 2337, 2434, 2448, 2471 |
Otitis externa | 214, 309, 465, 532, 540, 602 |
Otitis media | 38, 63, 128, 129, 131, 134, 136, 137, 138, 140, 167, 540, 576, 600, 709, 768, 769 |
Otosclerosis | 1261 |
Ovarian cancer | 25, 81, 122, 146, 164, 190, 237, 247, 338, 386, 489, 549, 559, 755, 791, 793, 895, 940, 1017, 1053, 1083, 1207, 1209, 1233, 1235, 1237, 1240, 1272, 1289, 1375, 1393, 1620, 1814, 2025, 2075, 2113, 2151, 2226, 2240, 2326, 2333, 2370, 2382, 2442, 2471, 2515, 2519, 2526 |
Ovarian dysgenesis | 2075 |
Ovarian hyperstimulation syndrome | 1969, 2075 |
Ovarian response to FSH | 2075 |
Overactive bladder | 304, 696, 753, 774 |
Overdose of anticholinesterase medications | 609 |
Ovulation induction | 156, 325, 777 |
Ovulatory failure | 172 |
Oxidative stress | 1152, 1470, 1606, 1815 |
Oxidized low-density lipoprotein | 1927 |
Oxysterol | 994, 1152 |
Oxysterol 7α-hydroxylase | 1927 |
Oxysterol 27-hydroxycholesterol | 1984 |
P | |
P28GANK | 896 |
p53 regulation | 2511 |
P450cam | 1816 |
Paclitaxel resistance | 2025 |
Paclitaxel/Carboplatin-induced myelosuppression | 1375 |
Paget disease of bone | 18, 108, 287, 562, 657, 742, 806 |
Pain | 7, 53, 70, 75, 94, 99, 105, 116, 154, 155, 180, 200, 234, 255, 291, 300, 301, 362, 364, 408, 409, 440, 463, 469, 509, 520, 527, 557, 565, 577, 673, 717, 758, 772, 803, 1375, 2167, 2323, 2399, 2478 |
Painful disorders | 5 |
Palliative treatment of hyperthyroidism in preparation for surgical treatment or radioactive iodine | 627 |
Palmar hyperhidrosis | 90 |
Palpebral and bulbar conjunctivitis | 316, 613 |
Pancreas | 1818 |
Pancreatic cancer | 274, 338, 897, 964, 1017, 1207, 1240, 2179, 2180, 2188, 2213, 2240, 2268, 2428, 2471 |
Pancreatic exocrine dysfunction | 678 |
Pancreatic insufficiency | 456 |
Pancreatitis | 368, 624, 1056 |
Pancreatoduodenectomy | 1418 |
Panic disorder | 23, 174, 317, 567, 681, 787, 1062, 1266, 2399 |
Papillary thyroid carcinoma | 1114, 2393 |
Papillary tumors | 68 |
Paracoccidioidomycosis | 407 |
Paralytic ileus | 217, 768 |
Paramyotonia congenita of von Eulenburg | 2388 |
Paraosteoarthropathy | 287 |
Parathyroid adenoma | 2268 |
Parathyroid carcinoma | 161 |
Parathyroid tumors | 1212 |
Parenteral nutrition | 694 |
Parenteral nutrition solution | 220 |
PARK genes | 1531 |
Parkinson disease 8 | 2254 |
Parkinson’s disease | 45, 72, 74, 94, 120, 166, 240, 335, 434, 609, 626, 647, 662, 665, 668, 678, 751, 767, 1056, 1062, 1152, 1264, 1264, 1324, 1343, 1529, 1819, 1969, 1989, 2001, 2003, 2005, 2078, 2081, 2098, 2112, 2113, 2116, 2128, 2193, 2254, 2260, 2264, 2283, 2288, 2291, 2295, 2308, 2326, 2337, 2420 |
Parkinsonian syndrome | 70, 85, 94, 106, 232, 264, 580, 621, 1989 |
Parkinsonism | 26, 120, 1981 |
Parotid and submandibular glands | 940 |
Paroxysmal atrial fibrillation | 618, 637 |
Paroxysmal AV junctional rhythm | 637 |
Paroxysmal extreme pain disorder | 2391 |
Paroxysmal nocturnal hemoglobinuria | 256, 2242 |
Paroxysmal supraventricular tachycardia | 12, 229, 618, 637 |
Paroxysmal ventricular tachycardia | 235,637 |
Partial or secondary generalized seizures | 79, 790 |
Partial seizures | 118, 177, 287, 297, 334, 414, 552, 584, 588, 738, 781, 784, 808 |
Patent ductus arteriosus | 383 |
Pathologic myopia | 790 |
Pathological hypersecretory conditions | 640, 645 |
PCSK9 (Proprotein convertase subtilisin/kexin type 9) | 1152 |
Pediatric acute nephritis | 449 |
Pediatric solid tumors | 103 |
Pediatric tuberculosis | 2402 |
Pediculus humanus infestations | 582 |
Pellagra | 522 |
Pelvic infections | 275 |
Pelvic inflammatory disease | 63, 137, 169 |
Pemphigus | 60, 607 |
Penicillin allergy | 2203, 2216 |
Peptic ulcer | 70, 347, 368, 462, 475, 624, 2155 |
Peptic ulcer (low dose aspirin-induced) | 1088 |
Percutaneous coronary intervention | 610, 739 |
Percutaneous transluminal coronary angioplasty | 746 |
Perennial allergic rhinitis | 69, 97, 142, 151, 157, 168, 187, 193, 304, 584, 764, 771 |
Periarthritis | 724 |
Periarticular ossification | 287 |
Periodontitis | 119, 162, 1153, 2213 |
Perioperative blood loss, prevention | 47 |
Perioperative genomic profiles | 1821 |
Perioperative nausea and vomiting | 620 |
Peripartum cardiomyopathy | 2358 |
Peripheral and cerebral ischemia | 565 |
Peripheral and pulmonary embolism | 797 |
Peripheral arterial disease | 356, 2426 |
Peripheral arterial occlusive disease | 2177 |
Peripheral nervous system | 1153 |
Peripheral neuropathy | 1274, 2341, 2422 |
Peripheral stem cell transplantation | 675 |
Peripheral vascular disease | 159, 355, 401, 522 |
Peripheral vasospastic disorders | 751 |
Peritonitis | 15, 310, 699 |
Permanent neonatal diabetes mellitus | 984, 2233 |
Pernicious anemia | 188 |
Peroxisomal acyl-CoA oxidase deficiency | 1042 |
Peroxisomal disorders | 1042 |
Peroxisome proliferator | 2106, 2340 |
Peroxisome proliferator-activated receptor alpha (PPARA) | 1393, 1620 |
Peroxisome proliferator-activated receptor gamma1 (PPARG1) | 995 |
Peroxisome proliferator activated receptor-gamma (PPARG)-coactivator 1alpha (PGC-1alpha) | 1471, 1927 |
Peroxisome proliferator-activated receptor-gamma (PPARG), Pioglitazone and Rosiglitazone | 1941 |
Peroxisome proliferator-activated receptor δ isosteric selenium agonists | 1153 |
Perpetrators of pharmacokinetic drug-drug interactions | 1324 |
Personality | 1537 |
Personality disorders | 2005 |
Personality traits | 2163, 2167 |
Personality traits and substance dependence | 1053 |
Pertussis | 255,276 |
Peters’ anomaly | 1343 |
Petit mal (absence) seizures | 475 |
Petit mal epilepsy | 463 |
Petit mal variant | 174 |
Peyronie’s disease | 607 |
P-Glycoprotein | 897, 898 |
Pharmacodynamics | 1153 |
Pharmacogenetic testing | 1393 |
Pharmacokinetics in children | 1822 |
Pharmacokinetics in the elderly | 1822 |
Pharmacoresistant temporal lobe epilepsy | 899 |
Pharyngitis/tonsillitis | 75, 128, 129, 130, 134, 136, 167 |
Pharyngitis/tonsillitis due to Streptococcus pyogenes | 63 |
Phase I and Phase II hepatic drug metabolism activities in human liver preparations | 1822 |
Phenolic function | 1823 |
Phenothiazine-induced bladder dysfunction | 80 |
Phenotypic appearance and neuropathology findings from patients with the known PARK mutations | 1531 |
Pheochromocytoma | 175, 484, 585, 586, 626, 2379 |
Philadelphia chromosome-positive chronic myelogenous leukemia | 376, 386 |
Phosphodiesterase type 5 (PDE5) | 1969 |
Phospholipase D | 1909 |
Phospholipids | 824, 1116, 1343, 1824, 2101 |
Photodynamic therapy | 1017 |
Physical activity/exercise | 1153 |
Pick’s disease | 2264, 2357 |
Piebaldism | 2238 |
Pim-1 kinase | 1017 |
Pinworm and roundworm infections | 453, 595, 631 |
Pituitary adenoma | 2268 |
Pituitary function test | 48, 628 |
Pituitary TSH suppression | 428 |
Pituitary-testicular function | 1969 |
Pityriasis (tinea) versicolor | 104, 158, 256, 553 |
Placenta | 822, 900, 995, 1018, 1290, 1343, 1826 |
Placental abruption | 2300 |
Plague | 704 |
Plaque psoriasis | 11, 108, 109, 192, 315, 384, 718, 778 |
Plasma apolipoprotein E | 1154 |
Plasma concentrations | 1444 |
Plasma volume expansion | 599 |
Plasmodium chabaudi malaria | 1912, 1927 |
Plasmodium falciparum malaria | 36, 51, 637, 1990 |
Plasmodium ovale malaria | 616 |
Plasmodium vivax malaria | 616 |
Platelet activating factor | 824, 901, 1092, 1111, 1270, 2013, 2195, 2270, 2340, 2345, 2367, 2372, 2381, 2453, 2462 |
Platelet aggregation | 2324, 2325 |
Platinum-based chemotherapy | 2029 |
Pleural mesothelioma | 1018 |
Pneumococcal disease, invasive, protection against | 39 |
Pneumoconiosis and occupationally related tumors | 1343 |
Pneumocystis carinii pneumonia | 58, 576, 768 |
Pneumocystis jiroveci (Pneumocystis carinii) pneumonia | 769, 770 |
Pneumonia | 131, 223, 309, 310, 340, 600 |
Poisoning | 145, 393 |
Pokemon gene transcription | 901 |
Polarized light irradiation | 1910 |
Poliomyelitis | 601 |
Polycystic ovary syndrome | 326, 1059, 1290, 1970, 2022, 2247, 2290, 2344 |
Polydipsia | 211 |
Polymicrobic infections | 377 |
Polypoidal choroidal vasculopathy | 1245 |
Polyuria | 211 |
Pompe disease | 20 |
Poor metabolizers | 1506 |
Porphyria | 1827 |
Porphyria cutanea tarda | 940, 1290, 1326 |
Porphyria variegate | 2129 |
Porphyrin metabolism | 1018 |
Porphyromonas gingivalis | 1154 |
Portal hypertension | 612 |
Portal venous thrombosis | 797 |
Portal-systemic encephalopathy | 413 |
Postabortion hemorrhage | 273, 477, 558 |
Post-encephalitic parkinsonism | 120, 677 |
Posterolateral lumbar spinal fusion | 271 |
Post-evacuation cholecystography | 687 |
Post-herpetic neuralgia | 116, 615 |
Post-menopausal endometriosis | 1970 |
Post-menopausal hormone therapy | 1154 |
Post-menopausal osteoporosis | 67, 110, 111, 112, 641, 657, 727, 806 |
Post-menopausal urogenital symptoms | 281 |
Post-myocardial infarction | 56, 79, 611, 742, 797 |
Post-operative antiemetic | 622, 624 |
Post-operative delirium | 1535 |
Post-operative nausea and vomiting | 620, 768, 773 |
Post-operative pain | 217, 424, 622, 666, 686, 724 |
Post-operative trauma | 141 |
Post-partum depression | 1264, 2259 |
Post-partum hemorrhage | 122 |
Post-stroke neurogenesis | 1970 |
Post-surgical analgesia | 648 |
Post-surgical and post-traumatic pain | 622, 666 |
Post-surgical pain | 116, 622, 666, 686 |
Post-traumatic epilepsy | 1154 |
Post-traumatic stress disorder | 567, 2062 |
Potassium deficiency | 604, 605 |
Potential health risks of complementary alternative medicines in HIV patients | 1828 |
PPARG agonist-induced edema and fluid retention | 2344 |
Prader-Willi syndrome | 697 |
Preanesthetic agent | 677 |
Precocious puberty | 349, 358, 1829 |
Precursor cell lymphoblastic leukemia-lymphoma | 1240, 2405 |
Prediction of anticancer drug activity | 1343 |
Prediction of oral drug interactions caused by CYP3A4 | 1829 |
Pre-eclampsia | 449, 1088, 1970, 2012, 2022, 2038, 2050, 2288, 2445, 2453 |
Pregnancy | 289, 1326, 1540, 1620, 1829, 1928 |
Pregnancy loss | 489, 494 |
Pregnancy-induced hypertension | 612, 2300 |
Pregnane X nuclear receptor | 1395 |
Pregnane X receptor | 902, 1154, 1830 |
Premalignant genital lesions | 359 |
Premature labor | 2120 |
Premature ovarian failure | 1928, 1971, 2069 |
Premature ventricular contractions | 618 |
Premenstrual dysphoric disorder | 317, 567, 681 |
Prenatal stress | 1971 |
Preoperative medication | 677 |
Preprolactin, glycoprotein alpha and luteinizing hormone beta gene expression | 1326 |
Prepubertal cryptorchidism | 156 |
Prepubertal gynecomastia in monozygotic twins with Peutz-Jeghers syndrome | 1971 |
Preterm cardiorespiratory disease | 1033 |
Prevention of cancer-chemotherapy-induced nausea and vomiting | 620, 773 |
Prevention of kidney stone | 745 |
Prevention of postoperative nausea and vomiting | 620, 768 |
Prevention of pregnancy | 776 |
Primary acute leukemia | 2179, 2180 |
Primary aldosteronism | 1941 |
Primary aldosteronism associated with subclinical Cushing’s syndrome | 1941 |
Primary antiphospholipid syndrome | 1201 |
Primary bile acid malabsorption | 2400 |
Primary biliary cirrhosis | 778, 1540, 1832, 1928, 2145 |
Primary brain tumors | 619, 903 |
Primary central nervous system lymphoma | 903 |
Primary congenital glaucoma | 1343 |
Primary cultured human hepatocytes | 903 |
Primary degenerative dementia | 342 |
Primary dysmenorrhea | 139, 223, 408, 457, 527, 724 |
Primary dystonia | 1154 |
Primary erythermalgia | 2391 |
Primary generalized tonic-clonic seizures | 423, 755 |
Primary hyperaldosteronism | 701 |
Primary hyperaldosteronism due to adrenal microadenoma | 1941 |
Primary hypercholesterolemia | 182, 442, 618, 667, 686 |
Primary hyperoxaluria (type I) | 1093 |
Primary immunodeficiency syndromes | 380 |
Primary insomnia | 2399 |
Primary keratoconjunctivitis | 767 |
Primary nephrotic syndrome | 2445 |
Primary open-angle glaucoma | 1073, 1154, 1344, 2193 |
Primary ovarian insufficiency | 1971 |
Primary pulmonary hypertension | 361, 533, 612, 684, 1047, 1203, 1620 |
Primary restless legs syndrome | 609, 665 |
Primary spontaneous intracerebral hemorrhage | 1052 |
Prion disease | 1154, 2350, 2351 |
PRNP Met129Val polymorphism in Alzheimer’s disease and prion disorders | 2350 |
Proatherogenic microbes | 1154 |
Probe substrates for clinical drug interaction studies | 1832 |
Procarcinogen activation | 1541 |
Proctitis | 466, 1833 |
Proctosigmoiditis | 466 |
Progesterone deficiency | 621 |
Progesterone receptor membrane component 1 (PGRMC1) | 1375 |
Progressive external ophthalmoplegia | 2335 |
Progressive external ophthalmoplegia with myoclonus | 2284 |
Progressive external ophthalmoplegia, proximal myopathy, and sudden death | 2285 |
Progressive familial intrahepatic cholestasis PFIC3 | 903 |
Progressive osseous heteroplasia | 2091 |
Progressive supranuclear palsy | 2264 |
Prolactin-secreting adenomas | 94 |
Proliferative diabetic retinopathy | 2177 |
Proliferative vitreoretinopathy | 2255 |
Prolonged bleeding time, brachydactyly and mental retardation | 2091 |
Promotion of weight gain | 550 |
Promoters for driving transgene expression | 1833 |
Prophylaxis of acute organ rejection in renal transplant | 688 |
Prostaglandin transporter | 1971 |
Prostate cancer | 2, 101, 193, 207, 237, 281, 282, 321, 349, 358, 407, 422, 495, 526, 712, 772, 791, 822, 903, 970, 995, 1018, 1114, 1186, 1209, 1267, 1272, 1291, 1326, 1344, 1835, 1971, 1985, 2018, 2110, 2116, 2120, 2151, 2156, 2177, 2188, 2216, 2241, 2255, 2275, 2331, 2341, 2370, 2416, 2422, 2426, 2442, 2489, 2510, 2515, 2528 |
Prostatic hyperplasia | 306, 1064, 1836 |
Prostatitis | 140, 307, 426 |
Protease inhibitor-associated hyperlipidemia | 1836 |
Proteasome | 1607, 1836 |
Protection against nicotine dependence | 2396 |
Protein C deficiency | 2353 |
Protein kinase Cβ (PKCβ) | 1928 |
Proteomics of human blood-brain barrier transporters | 903 |
Proteus infection | 29, 119, 128 |
Pruritic dermatosis | 73,610,613 |
Pruritus | 73, 155, 182, 188, 245, 368, 610 |
Pruritus ani | 610, 798 |
Pseudobulbar affect | 1545 |
Pseudoexfoliation syndrome | 1142 |
Pseudoexfoliative glaucoma | 2110, 2120 |
Pseudohermaphroditism | 2317 |
Pseudohypoaldosteronism | 1941 |
Pseudohypoaldosteronism, type 1 | 2391 |
Pseudohypoparathyroidism | 109 |
Pseudohypoparathyroidism (type IA) | 2091 |
Pseudohypoparathyroidism (type IB) | 2091 |
Pseudomembranous colitis | 155, 783 |
Pseudomonas aeruginosa infections | 29, 119, 131, 135, 594, 822 |
Pseudopseudohypo-parathyroidism | 2091 |
Pseudosymmetric solute translocation pathways | 904 |
Pseudovaginal perineoscrotal hypospadias | 2426 |
Pseudoxanthoma elasticum | 978, 2276 |
Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency | 2083 |
Psoriasis | 10, 42, 78, 179, 314, 473, 474, 672, 778, 940, 1155, 1228, 2126, 2136, 2216, 2220, 2456 |
Psoriasis vulgaris | 255, 2220 |
Psoriatic arthritis | 11, 60, 284, 348, 384, 2136, 2220, 2256, 2344 |
Psoriatic plaques | 764 |
Psychogeriatric patients | 1447 |
Psychomotor and focal seizures | 617 |
Psychosis | 95, 474, 580, 805, 810, 1155, 2399 |
Psychosis/schizophrenia | 474, 620, 635, 658, 710, 735, 736, 766, 805, 810, 1064, 1067, 1250, 1255, 1264, 1998, 2001, 2004, 2006, 2007, 2009, 2079, 2094, 2096, 2097, 2099, 2231, 2323 |
Psychostimulant abuse | 2323 |
Psychotic depression | 37 |
Psychotic disorders | 71, 319, 354, 442, 620, 736, 805, 2006 |
Pterygium | 2528 |
Puberty | 1838 |
PUFA metabolism (Arachidonic acid, Eicosatrienoic acid, Eicosapentaenoic acid, Docosahexaenoic acid) | 1910 |
Pulmonary alveolar proteinosis | 995 |
Pulmonary arterial hypertension | 27, 90, 525, 612, 684, 689, 762, 1047, 1345, 2014, 2302 |
Pulmonary artery pressure | 2328 |
Pulmonary atresia | 24 |
Pulmonary edema | 502 |
Pulmonary embolism | 6, 218, 263, 327, 356, 703, 744, 777, 797, 2325 |
Pulmonary emphysema | 745 |
Pulmonary function | 310 |
Pulmonary hypertension secondary to connective tissue disease | 689 |
Pulmonary hypertension, familial persistent, of the newborn | 683 |
Pulmonary stenosis | 24 |
Pulmonary thromboembolism | 797 |
Pulmonary tuberculosis | 191, 655, 2456 |
Pulmonary vasoconstriction | 751 |
Pulseless arrest | 785 |
Puromycin aminonucleoside-induced nephrosis | 1980 |
Purpura fulminans | 628 |
Pyelonephritis | 131, 162, 275 |
Pyodermas | 532 |
Pyorrhea | 255 |
Pyridoxine deficiency | 1607 |
Pyridoxine-dependent seizures | 632 |
Q | |
QT dispersion (QTd) | 1033 |
QT interval | 904, 1488, 1839 |
R | |
Rabies | 640, 641 |
Radiation | 1155 |
Radiation therapy | 1841 |
Radiation therapy-induced mucositis | 672 |
Radiation-induced apoptotic cell death | 905 |
Radioiodine ablation of thyroid tissue remnants | 737 |
Radiotracers | 905, 1019 |
RANKL antibody | 1972 |
Rasmussen’s encephalitis | 2094 |
Rat strain differences | 1607 |
Raynaud’s disease | 401, 612 |
Reactive arthritis | 2402 |
Receptor for activated C-kinase 1 (RACK1) | 1019 |
Receptor for advanced glycation end products (RAGE) | 1155 |
Recessive ataxia syndrome | 2335 |
Rectal cancer | 316, 2528 |
Recurrent cutaneous T-cell lymphoma | 608, 664, 796 |
Recurrent miscarriage | 1291, 2061 |
Reduce duodenal motility during diagnostic radiologic procedures | 624 |
Reduced triglycerides, susceptibility to | 611 |
Refractory acute lymphoblastic leukemia | 172 |
Refractory acute myeloid leukemia | 2347 |
Refractory constipation | 163 |
Refractory cutaneous T-cell lymphoma | 82 |
Refractory delirium tremens | 624 |
Refractory depression | 100 |
Refractory leukemia | 103 |
Refractory non-Hodgkin lymphoma | 311, 608, 757 |
Refractory rickets | 272 |
Refractory testicular tumors | 290 |
Regional analgesia | 464 |
Regional anesthesia | 622 |
Regulation of UGT1A1 by BRCA1 | 2489 |
Relapsing-remitting multiple sclerosis | 343 |
Relaxation of skeletal muscles | 646, 663, 705, 786 |
Removal of granulation tissue and warts | 685 |
Renal adenocarcinoma | 1910 |
Renal agenesis | 2379 |
Renal cancer | 17, 88, 292, 436, 456, 568, 698, 712, 722, 791, 941, 1274, 1345, 1420, 1843, 2270, 2297, 2337, 2385 |
Renal colic | 5 |
Renal CYP3A activity | 1843 |
Renal damage | 1155 |
Renal disease | 285, 2052 |
Renal dysfunction | 699 |
Renal failure in IgA nephropathy | 1088 |
Renal function | 906 |
Renal hypouricemia | 970 |
Renal insufficiency | 111, 511 |
Renal ischemia-reperfusion | 1607 |
Renal transplantation | 67, 906, 1843 |
Renal tubular dysgenesis | 1034, 1092, 2377 |
Resistance to platinating agents | 1193 |
Resistant depression | 1844 |
Respiratory allergies | 95 |
Respiratory depression | 244, 257 |
Respiratory diseases | 613, 764 |
Respiratory distress syndrome | 76 |
Respiratory infections | 131, 140, 700 |
Respiratory syncytial virus | 561,652 |
Respiratory tract diseases | 2456 |
Respiratory tract infections | 129, 132, 133, 134, 137, 140, 219, 341, 700 |
Response to diuretics | 1051 |
REST (RE1-silencing transcription factor) | 2174 |
Resting heart rate | 1073 |
Restless legs syndrome | 609, 665 |
Restoration of water/sodium losses | 691 |
Retinal artery occlusion | 2288 |
Retinoblastoma | 190, 198, 906, 941, 1019, 2207, 2291, 2375 |
Retinopathy | 2519 |
Retinopathy of prematurity | 2300 |
Retrolental fibroplasia | 750 |
Retroviral transfer of human CYP450 genes | 1845 |
REV-ERBalpha | 1929 |
Reversal of nondepolarizing neuromuscular blockers | 632 |
Reversible obstructive airway disease | 15, 31, 673 |
Rhabdomyolysis | 906, 1376, 1471, 1561, 1845, 2147, 2415 |
Rhabdomyosarcoma | 190, 196, 198, 791, 907, 2471 |
Rhabdomyosarcoma and neuroblastoma | 907 |
Rheumatic diseases | 613, 764 |
Rheumatic fever | 53, 576 |
Rheumatic heart disease | 2445, 2456 |
Rheumatism | 255, 772 |
Rheumatoid arthritis | 3, 5, 11, 42, 53, 60, 61, 116, 139, 141, 155, 192, 223, 284, 288, 291, 300, 321, 347, 348, 366, 383, 384, 408, 419, 440, 448, 459, 473, 506, 512, 550, 574, 597, 661, 708, 709, 724, 732, 738, 749, 764, 812, 907, 1062, 1155, 1191, 1201, 1228, 1237, 1327, 1918, 2058, 2139, 2140, 2145, 2198, 2200, 2211, 2216, 2278, 2290, 2295, 2337, 2347, 2408, 2439, 2456, 2465, 2471, 2515 |
Rheumatoid disorders | 190, 371 |
Rhinitis | 215, 368, 556 |
Rhinorrhea | 393, 771 |
Rho guanine nucleotide exchange factors PDZ-RhoGEF and LARG | 822 |
Riboflavin deficiency | 653 |
Ribosome inactivating protein | 2186 |
Rickets | 110 |
Rickettsia | 731 |
Rigidity | 368 |
Risk of coronary stent thrombosis | 610, 1420, 2226 |
Risk of metabolic syndrome, diabetes or vascular disease | 2249 |
Ritonavir-induced hyperlipidemia | 1929 |
RNA interference | 908, 1156, 1850, 1972 |
RNF2 (ring finger protein 2)(1q25.3) | 2174 |
Rosacea | 61, 78, 248 |
Rotavirus gastroenteritis | 668 |
Roundworms | 453, 631 |
Rubella | 379, 453, 669 |
Runx2 | 1973 |
S | |
S100A12 | 1156 |
Sacral chordoma | 909 |
Salivary glands | 1853 |
SALL4 | 1020 |
Salmonella infection | 39 |
Salmonellosis or shigellosis | 769 |
Salt | 1620 |
Salt sensitivity | 1395 |
Salt-sensitive essential hypertension | 612, 1052 |
Salt-sensitivity variants | 1853 |
Salzmann nodular degeneration | 1020 |
SANDO syndrome | 2335 |
Sarcoidosis | 2145, 2157, 2519 |
Sarcoma botryoides | 198 |
S-Containing drugs and xenobiotics oxygenated by FMO1 | 2065 |
Scabies | 188, 909 |
Scalp seborrheic dermatitis | 672, 679 |
Scavenger receptor class B type I (SR-BI) | 1156 |
Scedosporium apiospermum | 795 |
Scheie form of MPS I | 417 |
Schistosoma mansoni infection, susceptibility/resistance to | 612 |
Schistosomiasis | 612, 2216 |
Schizoaffective disorder | 1064 |
Schizophrenia | 49, 52, 95, 152, 178, 318, 319, 354, 374, 443, 474, 499, 541, 560, 582, 595, 620, 635, 658, 710, 735, 736, 766, 805, 810, 910, 1046, 1062, 1064, 1067, 1122, 1156, 1250, 1255, 1264, 1554, 1854, 1998, 2001, 2004, 2006, 2007, 2009, 2027, 2079, 2094, 2096, 2097, 2099, 2101, 2110, 2131, 2157, 2159, 2164, 2165, 2167, 2168, 2170, 2193, 2216, 2231, 2260, 2270, 2278, 2282, 2288, 2289, 2318, 2323, 2332, 2359, 2381, 2396, 2399, 2418, 2426, 2456, 2471, 2475, 2476 |
Schizophrenia, susceptibility to | 1064, 1067, 1250, 1254, 1264, 1998, 2001, 2004, 2006, 2007, 2079, 2094, 2096, 2097, 2099, 2231, 2323 |
Schizophrenia-related weight gain | 1064 |
Sciatica | 702 |
Scleroderma | 607 |
Sclerosing cholangitis | 910 |
Scorpion alcoholic extraction | 910 |
Scott syndrome | 822 |
Scurvy | 51 |
Seasonal affective disorder | 702, 2164 |
Seasonal allergic conjunctivitis | 409, 410, 424, 441, 457, 516, 543, 613 |
Seasonal allergic rhinitis | 69, 97, 121, 142, 151, 157, 168, 187, 193, 438, 500, 584, 764, 771 |
Seasonal changes | 1291, 1973 |
Seborrheic dermatitis | 78, 158, 179, 672 |
Second- and third-degree burns | 445, 685 |
Secondary amenorrhea | 456, 621 |
Secondary hyperparathyroidism | 109, 161, 566 |
Secondary Parkinson’s disease | 609 |
Secondary pulmonary hypertension | 612, 684, 689 |
Sedation | 145, 301, 624 |
Sedative/hypnotic withdrawal | 577 |
Seizure disorders | 174, 669, 781 |
Seizures | 278, 334, 584, 669, 781, 1535 |
Seizures and myoclonus | 1483, 1535 |
Selenium and vitamin E deficiency | 1904 |
Senile chorea | 729 |
Senile cognitive impairment | 166 |
Senile dementia | 272, 360, 620, 662, 750 |
Senile dementia of Alzheimer’s type | 141, 166, 620, 662, 713 |
Sepsis | 138, 251, 1291, 2050, 2216, 2256 |
Sepsis-induced drug metabolizing dysfunction | 1608 |
Septic arthritis | 309 |
Septic shock | 214, 785, 2456 |
Septicemia | 129, 132, 133, 137, 309, 310, 341, 549, 740 |
Serotonergic 5-HT2A receptor signaling | 1973 |
Serotonergic 5HTR6 compounds inducing hypophagia | 2170 |
Serotonin syndrome | 1536, 1555 |
Serotonin transporter | 1556 |
Serratia | 29 |
Serum incubation method | 1856 |
Serum lipid levels and metabolic syndrome | 2150 |
Serum opacity factor | 995 |
Serum thyroglobulin testing | 737 |
Severe acne | 169 |
Severe acute respiratory syndrome | 1034 |
Severe burns | 685 |
Severe combined immune deficiency | 2242 |
Severe combined immunodeficiency due to ADA deficiency | 1049 |
Severe combined immunodeficiency syndromes | 380 |
Severe congenital protein C deficiency | 628 |
Severe congestive heart failure | 241 |
Severe fibrosis | 1985 |
Severe heart failure | 701 |
Severe malaria anemia | 2216 |
Severe myoclonic epilepsy | 2386 |
Severe pain | 409, 427, 555, 717, 758, 803 |
Severe primary axillary hyperhidrosis | 90 |
Severely-restricted mobility | 263 |
Sevoflurane, Isoflurane, Propofol or Dexmedetomidine anesthesia | 959, 1930 |
Sex determination and disorders of sex development | 1973 |
Sex steroids | 1857, 1973 |
Sex-related differences | 1523, 1856 |
Sex-related metabolic profiles | 1559 |
Sexual development | 1973 |
Sexual dysfunction | 1536 |
Sexually-transmitted disease | 63 |
Sézary syndrome | 1993 |
Shigellosis | 39, 131 |
Shock | 15, 218, 241, 265, 535, 2157 |
Short bowel syndrome | 456 |
Short QT syndrome | 2236 |
Short QT syndrome 1 | 2232 |
Short QT syndrome 2 | 2236 |
Short stature | 697, 2088 |
Short-term treatment of insomnia | 677, 720, 765, 802, 809 |
Shoulder-hand syndrome | 724 |
Sialorrhea | 90, 368 |
Sick building syndrome | 1608 |
Sick sinus syndrome | 2390 |
Sickle cell anemia | 2125 |
Sickle-cell disease | 367, 1420 |
Side chain-oxidized oxysterols | 1985 |
Sigma receptors | 910, 1156 |
Silent myocardial ischemia | 1067 |
Silver-Russell syndrome | 2190 |
Single ventricle | 1941 |
Sinus bradycardia | 59 |
Sinus congestion | 771 |
Sinus tachycardia | 279 |
Sinusitis | 38, 512, 556, 630 |
SIRT1 | 822 |
Situational anxiety | 620 |
Sjögren’s syndrome | 143 |
Skeletal metastases | 704 |
Skeletal muscle pain | 123, 772 |
Skeletal muscle relaxant | 646, 747 |
Skeletal myopathy, responsive to riboflavin | 2285 |
Skin | 1861 |
Skin and skin structure infections | 129, 130, 131, 132, 133, 134, 135, 137, 140, 168, 430, 465, 483, 503, 540, 740, 741 |
Skin and soft tissue infections | 138, 341,700 |
Skin cancer | 1096, 2031, 2216, 2471 |
Skin cleanser | 148 |
Skin discoloration | 365 |
Skin disorders | 2154 |
Skin infections | 128, 129, 130, 131, 132, 133, 134, 135, 137, 140, 168, 341, 426, 430, 465, 483, 503, 519, 540, 639, 700, 707, 740, 741 |
Skin lesions | 26 |
Skin resurfacing | 764 |
Sleep disorders | 497 |
Sleep initiation and maintenance disorders | 791, 808 |
Small-cell lung cancer | 290, 755, 911, 941, 964, 1020, 1989, 2102, 2103, 2528 |
Small heterodimer partner (SHP) | 1930 |
Small interfering RNA (siRNA) | 911 |
Smallpox | 690, 2288 |
Smallpox vaccine | 690, 2288 |
Smith-Lemli-Opitz syndrome | 823 |
Smokeless tobacco | 1328 |
Smoking | 524, 784, 823, 1291, 1328, 1354, 1366, 1470, 1488, 1524, 1531, 1620, 1862, 2260 |
Sneezing | 771 |
S-Nitrosylation | 1157 |
Social anxiety disorder | 324, 567 ,681, 787, 1061 |
Social phobia | 787 |
Sodium depletion | 1941 |
Soft tissue infections | 700 |
Soft tissue or skeletal infections | 131 |
Soft tissue sarcoma | 88, 196, 198, 247, 791, 1189 |
Solar keratosis | 316 |
Solid tumor malignancies | 647, 712 |
Solid-organ transplantation | 1862 |
Solute carriers | 1863 |
Soman nerve gas exposure | 632 |
Somatic colon cancer | 2344 |
Somatic gastric cancer | 2224 |
Somatic gastrointestinal stromal tumor | 2329 |
Somatic mutations in pituitary adenomas | 2091 |
Somatic pilocytic astrocytoma | 2241 |
Somatoform disorders | 702 |
Sonic hedgehog | 1941 |
Sore throat pain | 585 |
Sorsby fundus dystrophy | 2450 |
Sour stomach | 160, 296 |
Spasm | 677 |
Spastic colon | 768 |
Spasticity | 200, 790 |
Species differences | 1329, 1366, 1396, 1608, 1620 |
Species differences and evolutionary origins | 1973 |
Sperm | 1292 |
Spermatogenesis | 156, 325, 326, 1975 |
Sperm whale skin biopsies | 1292 |
Sphingomyelins | 995, 1157, 1178, 1183 |
Sphingosine kinase | 941 |
Sphingosine 1-phosphate | 2212, 2237 |
Sphingosine-1-phosphate receptors | 1157 |
Spina bifida | 2297, 2337 |
Spina bifida and neural tube defect | 2405 |
Spinal and bulbar muscular atrophy | 1186 |
Spinal anesthesia | 619, 706, 730 |
Spinal cord injury | 65, 200, 984 |
Spondylolisthesis | 271 |
Spontaneous abortion | 1930, 2136 |
Spontaneous preterm birth | 2361 |
Sporadic amyotrophic lateral sclerosis | 656, 1111, 2104, 2528 |
Sporadic breast cancer | 1196 |
Sporadic colorectal adenocarcinomas | 1046 |
Sporadic solitary aldosterone- and cortisol-co-secreting adenomas | 1942 |
SPRED2 (sprouty-related protein with EVH1 domain 2) | 1942 |
Squamous cell carcinoma | 88, 913 |
Squamous cell carcinoma of the head and neck | 143, 237, 367, 2505 |
Squamous cell carcinoma of the larynx and hypopharynx | 1608, 1623, 1590, 1864 |
Squamous cell lung carcinoma | 1292 |
SSRI-induced sexual dysfunction | 800 |
SSRI-related hyponatremia | 1479, 1536 |
SSRIs, TCAs and neuroleptics | 1479 |
Stable angina | 788 |
Stable monomorphic VT | 618 |
Staining of anterior capsule of the lens | 774 |
Staphylococcal infections | 39, 309, 337, 508, 639, 654, 741, 783 |
Staphylococcus aureus bacteremia | 201, 504, 639, 741 |
STAT3 decoy oligodeoxynucleotides | 913 |
Static magnetic field | 913 |
Stature quantitative trait locus | 1237 |
Status asthmaticus | 673 |
Status epilepticus | 439, 781 |
Stearoyl-Coenzyme A | 2106 |
Steatohepatitis | 78 |
Steatosis | 2292 |
Stem cells | 941, 1366, 1609, 1930 |
Stent thrombosis | 610, 914, 1396 |
Steroid receptor coactivator 2 (SRC-2) | 1975 |
Steroid-induced osteonecrosis | 914 |
Steroidogenic acute regulatory protein | 996 |
Steroidogenic factor-1 (SF-1) | 1942 |
Steroid-resistant asthma | 914 |
Sterol carrier protein-2 | 1930 |
Stevens-Johnson syndrome | 2131, 2134 |
Stimulation of pancreatic secretion for analysis | 687 |
Stomach | 1869 |
Stomach cancer | 316, 494 |
Stomatitis | 73, 119, 255 |
Strabismus | 90 |
Strategies for minimizing mechanism-based inhibition of CYP3A4 | 1869 |
Streptococcal or enterococcal endocarditis | 39, 309, 549, 704 |
Streptococcal serum opacity factor | 1157 |
Streptococcus pneumoniae | 63, 134 |
Streptozotocin-induced diabetic nephropathy | 1621 |
Stress | 343, 2306 |
Stress/anxiety | 144, 620, 702 |
Stress-related diseases | 2062 |
Stroke | 53, 176, 200, 523, 611, 643, 740, 823, 941, 1034, 1079, 1118, 1228, 1270, 1421, 1869, 1907, 1910, 1942, 2038, 2048, 2050, 2198, 2300, 2337 |
Stroke, susceptibility to | 1079, 1270, 2337 |
Stroke-like-episodes | 2284 |
Strongyloidiasis | 403, 733 |
Structure-activity relationship analysis of CYP450 metabolism | 1870 |
ST-segment elevation myocardial infarction | 263, 651, 722, 739 |
Sturge-Weber syndrome with congenital glaucoma | 1345 |
Subacute sclerosing panencephalitis | 2203 |
Subacute stent thrombosis | 610, 740 |
Subarachnoid hemorrhage | 528, 759, 1158 |
Substance abuse | 2007, 2162, 2164 |
Substrate preferences | 1870 |
Substrate-dependent activity of CYP2D6 isoenzymes | 1562 |
Sucrase deficiency | 671 |
Sudden cardiac arrest | 1034 |
Sudden cardiac death | 2390 |
Sudden death | 2236 |
Sudden infant death syndrome | 2159, 2198, 2216, 2282, 2285 |
Sudden sensorineural hearing loss | 1292 |
Suicidal behavior | 2396 |
Suicidal ideation | 914 |
Suicide | 2165 |
Sulfonylurea-induced hypoglycemia | 1396 |
Sulfonylurea receptor 2A | 985 |
Sulfonylurea receptor 2B | 985 |
Sulfotransferases | 1870 |
Sunburn | 73 |
Superficial eye infections | 602, 748, 768 |
Superficial mycoses | 177 |
Suppression of Rh isoimmunization | 651 |
Suprapubic pain | 307 |
Supraventricular tachyarrhythmias | 227, 229, 279, 308, 623, 626, 788 |
Susceptibility to arsenic-induced diseases | 1190, 1220 |
Susceptibility to atypical hemolytic uremic syndrome | 2449 |
Susceptibility to carcinogens | 2120 |
Susceptibility to cleft lip/palate | 2291 |
Susceptibility to diabetic nephropathy | 2129 |
Susceptibility to different types of cancer | 2031 |
Susceptibility to essential hypertension | 612, 1063, 1066, 1068, 1071, 1077, 1081, 1197, 2093 |
Susceptibility to hip fracture | 2227 |
Susceptibility to obsessive-compulsive disorder | 2096 |
Susceptibility to recurrent viral infections | 2059 |
Susceptibility to UV-induced sun damage | 2267 |
Susceptibility to West Nile virus | 1228 |
Sweetening agent | 698 |
Sympathetic ophthalmia | 764 |
Sympathoadrenal, metabolic, and hormonal balance | 2306 |
Symptomatic parkinsonism | 120 |
Syndrome of inappropriate ADH secretion (SIADH) | 754 |
Synovitis | 764 |
Syphilis | 248, 255, 276, 731 |
Systemic carnitine deficiency | 425 |
Systemic fungal infections | 407 |
Systemic juvenile rheumatoid arthritis | 2207 |
Systemic lupus erythematosus | 764, 1201, 1421, 1609, 1975, 1985, 2038, 2056, 2059, 2110, 2145, 2157, 2203, 2208, 2216, 2295, 2439, 2456, 2466 |
Systemic mastocytosis | 187 |
Systemic sclerosis | 1201, 1562, 2139, 2300, 2439 |
Systolic blood pressure in preterm infants | 1562 |
Systolic hypertension | 153, 612 |
T | |
Tachycardia | 355, 1073 |
Tachypnea | 301 |
Tamoxifen resistance | 2026 |
Tangier disease | 823 |
Tardive dyskinesia | 710, 729, 750, 790, 1258, 1330, 1566, 1875, 2002, 2004, 2422 |
Tauopathies | 1158, 2264 |
Tau-tubulin kinase-1 | 1158 |
T-cell acute lymphoblastic leukemia | 517, 966 |
T-cell leukemia | 608 |
T-cell lymphoblastic lymphoma | 517, 608, 1875 |
T-cell prolymphocytic leukemia, sporadic | 608 |
TGFβ1 | 1931 |
Telangiectasia | 2471 |
Telomere shortening | 1976 |
Temporal arteritis | 764 |
Temporomandibular joint pain | 123 |
Tenascin-C | 917 |
Tendinitis | 383, 709, 724 |
Test to evaluate thyroid function | 628, 692 |
Testicular cancer | 88, 146, 164, 190, 198, 290, 374, 791, 2272 |
Testicular germ cell cancer | 1329, 1877, 2335 |
Testicular steroids | 1354, 1609 |
Testicular tumors | 198, 290, 790 |
Testotoxicosis | 1961 |
Tetanus | 152, 379, 472, 729 |
Tetrahydrobiopterin (BH4) responsive phenylketonuria | 674 |
Tetrahydrobiopterin-deficient hyperphenylalaninemia due to GTP cyclohydrolase I deficiency | 2082 |
Thalassemia | 206, 1330, 1878 |
Thalidomide-related neuropathy | 823 |
Therapeutic abortion | 1965 |
Therapy-related acute myeloid leukemia (t-ML) | 2274, 2308 |
Thiamine deficiency | 733 |
Third degree burns | 685 |
Thrombocytopenia | 41, 260, 420, 546, 665, 2200, 2227 |
Thrombocytopenic purpura | 380, 2227 |
Thromboembolic disease | 6, 233, 420, 797 |
Thromboembolic stroke | 611, 2203 |
Thromboembolism | 356, 797, 2050, 2353 |
Thrombophilia | 2449 |
Thrombophilia due to activated protein C resistance | 2050 |
Thrombophilia due to factor V Leiden | 2050 |
Thromboprophylaxis | 196 |
Thrombosis | 48, 199, 1158, 2227, 2288 |
Thrombotic stroke | 233, 611, 740 |
Thymine | 1995 |
Thymocytes | 919 |
Thymocyte and lymphocyte proliferation | 996 |
Thyroid cancer | 247, 692, 737, 1021, 2018, 2026, 2297, 2450, 2489, 2511 |
Thyroid disease | 919, 1992, 2434 |
Thyroid dysfunction | 2230 |
Thyroid dyshormogenesis | 2392 |
Thyroid function | 628, 692 |
Thyroid hormone | 1991, 2417 |
Thyroid nodules | 737 |
Thyroid papillary carcinoma | 2270 |
Thyroidectomy | 737 |
Thyroiditis | 737 |
Thyrotoxic crisis | 627 |
Thyrotoxicosis | 737 |
Ticlopidine-induced hepatotoxicity | 2131 |
Tie1 | 1158 |
Time-dependent CYP450 inhibition | 1880 |
Tinea corporis | 104, 158 |
Tinea cruris | 104, 158 |
Tinea pedis | 104, 158 |
TNFα | 1610, 1931 |
Tinnitus | 161, 342, 2399 |
TMCC2 | 1158 |
Tobacco | 1292, 1610 |
Tobacco smoking | 1067 |
Tobacco use disorder | 1253, 1255, 1610, 1989, 2006, 2259 |
Tobacco-related cancers | 2505 |
Tocopherol-ω-hydroxylase | 1910 |
Toll-like receptor 2 (TLR2) | 1159 |
Toll-like receptor 4 (TLR4) | 1159 |
TOMM40 poly-T variants | 1159 |
Tonic-clonic (grand mal) seizures | 287, 617 |
Tonsillar disease | 2453 |
Tonsillitis | 255 |
Tooth agenesis | 1249 |
Toothache | 234 |
Topical infections | 608 |
Topoisomerase I | 1022 |
Torg-Winchester syndrome | 2276 |
Torsades de pointes | 449, 1882, 2232 |
Torsades de pointes, drug-associated | 2232 |
Torulopsis glabrata | 39 |
Tourette’s syndrome | 354, 591, 729, 805, 2002, 2198 |
Toxoplasma gondii | 633, 708, 768 |
Toxoplasma gondii encephalitis | 58, 2141 |
Toxoplasma gondii infection | 633, 708, 768 |
Toxoplasmosis | 633, 708, 768 |
Trace metal deficiencies | 757 |
Trachoma | 707, 2153, 2216 |
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) | 919 |
TRAIL death receptor 5 (DR5) | 919 |
Transcription factor | 2071 |
Transcriptional activation of CYP3A4 | 2150 |
Transcriptome | 1159 |
Transforming growth factor beta (TGFB) | 1610 |
Transforming growth factor-beta1 (TGFB1) | 996, 1610 |
Transient ischemic attacks | 6, 233, 523, 797 |
Transient neonatal diabetes mellitus | 985, 2234 |
Transitional cell carcinoma | 793 |
Transkingdom RNAi | 920 |
Transplant recipients | 1883 |
Transplant-associated coronary disease | 2177 |
Transplant-free survival for single ventricle patients | 2012 |
Transporter-enzyme interactions | 1883 |
Transurethral prostatic resection | 698 |
Traumatic brain injury | 342, 1159 |
Traumatic spinal cord injury | 1159 |
Travelers’ diarrhea | 655, 761, 769 |
Treatment of acute lymphocytic leukemia | 723, 792 |
Treatment of growth failure associated with chronic renal insufficiency | 697 |
Treatment of short stature or growth failure associated with short stature homeobox gene deficiency | 697 |
Treatment of short-bowel syndrome | 697 |
Treatment of tinea versicolor and acne | 553, 679, 695, 707, 725 |
Treatment-resistant depression | 774 |
Trefoil factor 1 (TTF1) | 1976 |
Tremor | 368, 1376 |
Treponema pallidum | 575 |
Trichinosis | 613, 733 |
Trichomoniasis | 743 |
Tricuspid atresia | 24 |
Trifluoromethylpyrimidine class of tyrosine kinase 2 (PYK2) inhibitors | 1885 |
Trigeminal neuralgia | 748 |
Trigeminal/glossopharyngeal/diabetic neuralgia | 118 |
Triglycerides | 2196, 2210, 2301, 2318, 2338, 2463 |
Triiodothyronine | 1046, 1054, 1183, 1223, 1262, 1613, 1885, 1992, 2054, 2074, 2075, 2082, 2086, 2118, 2125, 2159, 2253, 2275, 2276, 2318, 2333, 2376, 2447, 2463 |
Trilostane (3β-hydroxysteroid dehydrogenase inhibitor) | 1977 |
Trimethylaminuria | 2068 |
Trophoblastic neoplasms | 473 |
Tuberculosis | 32, 68, 116, 285, 286, 397, 613, 631, 654, 704, 920, 1887, 2067, 2183, 2220, 2402, 2407, 2466, 2515 |
Tularemia | 704 |
Tumor necrosis factor-alpha (TNF) | 920, 996, 1022, 1145 |
Tumor proliferation | 1621 |
Tumorigenesis | 2072 |
Tumor-induced angiogenesis | 2276 |
Turner’s syndrome | 697 |
Type 1 Gaucher’s disease | 786 |
Type III hyperlipoproteinemia | 1159 |
Type III hyperlipoproteinemia associated with APOE deficiency | 1160 |
Type III hyperlipoproteinemia due to APOE4-Philadelphia | 1160 |
Typhoid fever | 162, 255, 769, 2145 |
Tyroid carcinoma | 2515 |
U | |
Ubiquitin-dependent proteasomal degradation | 1610 |
UDP-glucuronosyltransferase 2B7 modulation | 1887 |
UGT1A9 regulation by BRCA1 | 2502 |
UHRF1 | 921 |
Ulcerative colitis | 66, 363, 384, 466, 543, 699, 708, 921, 970, 1258, 1355, 2116, 2120, 2150, 2200, 2217, 2312, 2344, 2456, 2528 |
Ulcerative gastroesophageal reflux disease | 415, 640 |
Ultra-rapid metabolizers | 1507 |
Ultrasound | 921 |
Ultraviolet-induced dyschromia | 365 |
Unresponsive hyperinsulinemic hypoglycemia | 985 |
Unstable angina | 87, 176, 199, 263, 327, 610, 738, 739, 788 |
Upper airway secretions | 347 |
Upper and lower respiratory tract infections | 138, 255, 700 |
Upper gastrointestinal tract cancer | 1096 |
Upper GI bleeding | 240 |
Upper respiratory allergies | 630 |
Urate/uric acid and gout | 617, 1022 |
Urea cycle disorder | 693 |
Ureteral spasm | 624 |
Urethra gonorrhea | 700, 731 |
Urethritis | 63, 307, 540 |
Urethrocystitis | 307 |
Urethrotrigonitis | 307 |
Uric acid | 647 |
Urinary bladder neoplasms | 2480 |
Urinary bladder spasm | 624 |
Urinary burning | 255 |
Urinary incontinence | 265, 304, 1977 |
Urinary outflow obstruction | 244, 306 |
Urinary retention | 306 |
Urinary tract infection | 8, 119, 128, 129, 131, 132, 133, 134, 137, 138, 162, 191, 242, 255, 275, 310, 330, 377, 471, 509, 532, 536, 583, 708, 709, 740, 768, 769, 1905, 2453 |
Urine alkalinization | 604, 606 |
Urokinase plasminogen activator | 1160 |
Urolithiasis | 2516 |
Urothelial carcinoma | 793, 1611, 2112, 2113 |
Urticaria | 121, 142, 151, 168, 193, 215, 773 |
Uterine atony | 273 |
Uterine leiomyoma | 422, 1345, 2528 |
Uterine sarcomas | 198 |
Uveal melanoma | 1241 |
Uveal tract inflammation | 359 |
Uveitis | 59, 314, 316, 764 |
V | |
Vaginal irritation | 608 |
Vancomycin-resistant Enterococcus faecium infections | 430, 639 |
Vancomycin-sensitive Enterococcus faecalis | 741 |
Varicella | 379,453 |
Varicella zoster | 10 |
Varicella zoster virus in pregnant women | 785 |
Varicocele-associated male infertility | 1977 |
Varicose veins | 502, 695 |
Varicosis | 1621 |
Vascular calcification | 1160 |
Vascular dementia | 342, 523, 1160, 2456 |
Vascular disorders | 523, 2300 |
Vascular factors | 1160 |
Vascular failure | 587 |
Vascular headaches | 273, 479 |
Vascular injury | 1160 |
Vasoactive intestinal peptide, 4-chloro-Phe6-Leu17- | 2447, 2520 |
Vasodilatory shock | 785 |
Vasomotor rhinitis | 62, 95, 121 |
Vasospastic (Prinzmetal’s) angina | 34,788 |
Vein graft disease | 1160 |
Venoocclusive disease | 1889 |
Venous thromboembolism | 199, 628, 797, 1398, 2203, 2325 |
Venous thrombosis | 6, 218, 356, 797, 2050, 2364 |
Ventricular arrhythmias/tachycardia | 5, 398, 429, 485, 501, 698, 699 |
Ventricular asystole | 59 |
Ventricular fibrillation | 32, 785 |
Ventricular premature complexes | 235 |
Ventricular tachycardia | 32, 308, 501, 618, 626, 785, 1073, 2390 |
Vernal conjunctivitis | 187, 435, 457 |
Vernal keratitis | 187, 435 |
Vernal keratoconjunctivitis | 187, 435 |
Vertebral fractures | 1977 |
Vertigo | 161, 189, 230, 342, 454, 710, 791 |
Vestibular disorders | 161 |
Vestibular vertigo | 313, 791 |
Vincent’s infection | 119 |
Viral croup | 266 |
Viral infection | 2180 |
Visceral pain syndromes | 234, 287 |
Visual disorders | 342 |
Vitamin A deficiency | 651 |
Vitamin B6 deficiency | 632 |
Vitamin B12 deficiency | 188, 366 |
Vitamin C deficiency | 1611 |
Vitamin D deficiency | 154 |
Vitamin D3 hydroxylase | 1986 |
Vitamin D3 25-hydroxylases | 1621 |
Vitamin D-dependent rickets (type II) | 2516 |
Vitamin deficiencies | 795 |
Vitamin E deficiency | 750 |
Vitamin K1 oxidase | 1911 |
Vitiligo | 474, 500, 1215 |
Vitreal kinetics | 924 |
Vomiting | 161, 230,239 |
von Hippel-Lindau disease | 1221 |
von Willebrand disease | 44, 211 |
Vulvar and vaginal atrophy | 281, 283 |
Vulvitis | 798 |
Vulvovaginal candidiasis | 104, 177, 310, 486, 681, 725, 744 |
W | |
Waldenström’s macroglobulinemia | 732 |
Warts | 115, 672, 766 |
Water channel | 1895 |
WAVE1 | 924 |
Wegener’s granulomatosis | 190 |
Weight gain | 1064, 1524, 1549 |
Weight loss | 78, 800, 1046, 1082 |
Wernicke’s encephalopathy | 733 |
Whipworms | 453 |
White matter changes | 1161 |
Whole blood serotonin | 2227 |
Wilms’ tumor | 198, 247, 791, 925 |
Wilson’s disease | 574, 766, 2198 |
Wiskott-Aldrich syndrome | 380 |
Wolff-Parkinson-White syndrome | 623 |
Wound cleansing, irrigation, and flushing | 691 |
Wound irrigation | 691, 692 |
Wounds and injuries | 449, 701, 805 |
X | |
Xanthelasma | 675 |
Xanthinuria | 2525 |
Xenobiotics | 925, 961, 1096, 1471, 2105, 2314 |
Xenobiotic and endobiotic metabolism | 1905 |
Xeroderma pigmentosum | 2032 |
Xeroderma pigmentosum, complementation group A | 2526 |
Xerostomia | 590, 672 |
X-linked adrenoleukodystrophy | 1911 |
X-linked cutis laxa | 1193 |
X-linked immunodeficiency | 380 |
X-linked mental retardation | 2094 |
X-linked mental retardation type 94 (MRX94) | 2094 |
Z | |
Zinc and Paraquat co-exposure | 1611 |
Zinc supplement | 805 |
ZFAND6 function | 2529 |
Zollinger-Ellison syndrome | 279, 296, 415, 564, 640 |